UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                  to                  

 

PYROPHYTE ACQUISITION CORP.
(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-40957   N/A
(State or other jurisdiction of
incorporation or organization)
  (Commission File Number)   (IRS Employer
Identification No.) 

 

3262 Westheimer Road
Suite 706
Houston, Texas
  77098
(Address Of Principal Executive Offices)   (Zip Code)

 

+1 (345) 769-4900
Registrant’s telephone number, including area code

 

Not Applicable
(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Title of Each Class:

  Trading Symbol:   Name of Each Exchange on Which Registered:
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant   PHYT.U   New York Stock Exchange
Class A Ordinary Shares, par value $0.0001 per share   PHYT   New York Stock Exchange
Redeemable Warrants, each exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share   PHYT WS   New York Stock Exchange

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer  
Non-accelerated filer Smaller reporting company  
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☐

 

As of November 20, 2023 the Registrant had 14,005,087 Class A ordinary shares, $0.0001 par value per share, issued and outstanding.

 

 

 

 

 

PYROPHYTE ACQUISITION CORP.

 

FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2023

 

TABLE OF CONTENTS

 

    Page
PART I – FINANCIAL INFORMATION   1
Item 1. Condensed Financial Statements   1
  Condensed Balance Sheets as of September 30, 2023 (unaudited) and December 31, 2022   1
  Unaudited Condensed Statements of Operations for the three and nine months ended September 30, 2023 and 2022   2
  Unaudited Condensed Statements of Changes in Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit for the three and nine months ended September 30, 2023 and 2022   3
  Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2023 and 2022   4
  Notes to Unaudited Condensed Financial Statements   5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   21
Item 3. Quantitative and Qualitative Disclosures About Market Risk   31
Item 4. Controls and Procedures   31
PART II – OTHER INFORMATION   32
Item 1. Legal Proceedings.   32
Item 1A. Risk Factors.   32
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   32
Item 3. Defaults Upon Senior Securities   32
Item 4. Mine Safety Disclosures   32
Item 5. Other Information   32
Item 6. Exhibits   33

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Condensed Financial Statements.

 

PYROPHYTE ACQUISITION CORP.

CONDENSED BALANCE SHEETS

 

   September 30,   December 31, 
   2023   2022 
   (Unaudited)     
ASSETS        
Cash  $1,933   $13,372 
Prepaid expenses   56,180    298,422 
Extension contribution due from Sponsor   480,000    
 
Due from related party   
    49,500 
Total current assets   538,113    361,294 
Investments and cash held in Trust Account   97,110,088    209,651,193 
Total Assets  $97,648,201   $210,012,487 
           
LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT          
Accounts payable  $63,842   $
 
Promissory note – extension loan   480,000    
 
Promissory note – working capital loan   177,055    
 
Due to related party   15,000    
 
Accrued expenses   525,209    222,020 
Total current liabilities   1,261,106    222,020 
Deferred underwriting fees payable   8,443,750    8,443,750 
Derivative warrant liabilities   1,314,218    1,516,406 
Deferred legal fees   2,034,799    1,322,174 
Total Liabilities   13,033,873    11,504,350 
           
Commitments and Contingencies (Note 5)   
 
    
 
 
Class A ordinary shares subject to possible redemption, $0.0001 par value; 8,973,837 and 20,125,000 shares at $10.86 and 10.41 per share at September 30, 2023 and December 31, 2022, respectively   97,490,079    209,551,185 
           
Shareholders’ Deficit          
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding   
    
 
Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 5,031,250 and zero shares issued or outstanding at September 30, 2023 and December 31, 2022, respectively (excluding 8,973,837 and 20,125,000 shares subject to possible redemption, respectively)   503    
 
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 0 and 5,031,250 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively   
    503 
Additional paid-in capital   
    
 
Accumulated deficit   (12,896,254)   (11,043,551)
Total shareholders’ deficit   (12,895,751)   (11,043,048)
Total Liabilities, Ordinary Shares Subject to Possible Redemption, and Shareholders’ Deficit  $97,648,201   $210,012,487 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

1

 

 

PYROPHYTE ACQUISITION CORP.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

   For The
Three Months
Ended
September 30,
2023
   For The
Three Months
Ended
September 30,
2022
   For The
Nine Months
Ended
September 30,
2023
   For The
Nine Months
Ended
September 30,
2022
 
General and administrative expenses  $547,392   $254,584   $1,574,892   $2,034,395 
Loss from operations   (547,392)   (254,584)   (1,574,892)   (2,034,395)
Change in fair value of derivative warrant liabilities   683,395    2,830,625    202,188    8,271,893 
Gain on investments held in Trust Account   1,226,102    1,023,730    4,723,284    1,391,133 
Other income   
-
    66    
-
    83 
Net income  $1,362,105   $3,599,837   $3,350,580   $7,628,714 
Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted
   8,973,837    20,125,000    13,589,520    20,125,000 
Basic and diluted net income per share, Class A ordinary shares subject to possible redemption
  $0.10   $0.14   $0.18   $0.30 
Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted
   5,031,250    5,031,250    5,031,250    5,031,250 
Basic and diluted net income per share, non-redeemable ordinary shares
  $0.10   $0.14   $0.18   $0.30 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

2

 

 

PYROPHYTE ACQUISITION CORP.

CONDENSED STATEMENTS OF ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND
SHAREHOLDERS’ DEFICIT

For the three and nine months ended September 30, 2023

(Unaudited)

 

   Ordinary Shares Subject
to Possible Redemption
   Ordinary Shares   Additional       Total 
   Class A   Class A   Class B    Paid-In    Accumulated    Shareholders’ 
     Shares      Amount      Shares      Amount      Shares      Amount     Capital    Deficit    Deficit 
Balance as of January 1, 2023   20,125,000   $209,551,185    -   $-    5,031,250    503   $-   $(11,043,551)  $(11,043,048)
Remeasurement of Class A ordinary shares to redemption value   -    2,347,624    -    -    -    -    -    (2,347,624)   (2,347,624)
Net income   -    -    -    -    -    -    -    1,005,015    1,005,015 
Balance as of March 31, 2023   20,125,000   $211,898,809    -   $-    5,031,250   $503   $-   $(12,386,160)  $(12,385,657)
Redemption of Class A ordinary shares   (11,151,163)   (117,744,389)   -    -    -    -    -    -    - 
Conversion of Class B ordinary shares to Class A ordinary shares   -    -    5,031,250    503    (5,031,250)   (503)               -    -    
-
 
Remeasurement of Class A ordinary shares to redemption value   -    1,309,557    -    -    -    -    -    (1,309,557)   (1,309,557)
Extension contribution due from Sponsor        

320,000

    -    
-
    -    
-
    
-
    
-
    
-
 
Net income   -    -    -    -    -    -    -    983,460    983,460 
Balance as of June 30, 2023 (as revised)   8,973,837   $95,783,977    5,031,250   $503    -   $-   $-   $(12,712,257)  $(12,711,754)
                                              
Remeasurement of Class A ordinary shares to redemption value   -    1,226,102    -     
- 
    -    -    -    (1,546,102)   (1,546,102)
Extension contribution due from Sponsor        

480,000

    -    
-
    -    
-
    
-
    
-
    
-
 
Net income   -    -    -    -    -    -    -    1,362,105    1,362,105 
Balance as of September 30, 2023   8,973,837   $97,490,079    5,031,250   $503    -   $-   $-   $(12,896,254)  $(12,895,751)

 

For the three and nine months ended September 30, 2022

(Unaudited)

 

   Ordinary Shares Subject
to Possible Redemption
   Ordinary Shares   Additional       Total 
   Class A   Class A   Class B   Paid-In   Accumulated   Shareholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balance as of January 1, 2022   20,125,000   $206,281,250    
-
   $
-
    5,031,250    503   $
            -
   $(18,416,733)  $(18,416,230)
Net income    -    
-
    -    
-
    -    
-
    
-
    1,119,132    1,119,132 
Balance as of March 31, 2022    20,125,000   $206,281,250    
-
   $
-
    5,031,250   $503   $
-
   $(17,297,601)  $(17,297,098)
Remeasurement of Class A ordinary shares to redemption value   -    285,449         
 
    -    
-
    
-
    (285,449)   (285,449)
Net income   -    
-
    -    
-
    -    
-
    
-
    2,909,745    2,909,745 
Balance as of June 30, 2022    20,125,000   $206,566,699    
-
   $
-
    5,031,250   $503   $
-
   $(14,673,305)  $(14,672,802)
                                              
Remeasurement of Class A ordinary shares to redemption value   -    1,023,730              -    
-
    
-
    (1,023,730)   (1,023,730)
Net income   -    
-
    -    
-
    -    
-
    
-
    3,599,837    3,599,837 
Balance as of September 30, 2022    20,125,000   $207,590,429    
-
   $
-
    5,031,250   $503   $
-
   $(12,097,198)  $(12,096,695)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

3

 

 

PYROPHYTE ACQUISITION CORP.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 

   FOR THE
NINE MONTHS
ENDED
SEPTEMBER 30,
2023
   FOR THE
NINE MONTHS
ENDED
SEPTEMBER 30,
2022
 
Cash Flows from Operating Activities        
Net income  $3,350,580   $7,628,714 
Adjustments to reconcile net income to net cash used in operating activities:          
Gain on investments held in Trust Account   (4,723,284)   (1,391,133)
Change in fair value of derivative warrant liabilities   (202,188)   (8,271,893)
Changes in operating assets and liabilities:          
Prepaid expenses   242,242    254,098 
Due from related party   49,500    (39,500)
Other current assets   
-
    25,000 
Deferred legal fees   712,625    1,142,012 
Accounts payable   63,842    
-
 
Accrued expenses   303,189    (48,918)
Net cash used in operating activities   (203,494)   (701,620)
Cash Flows from Investing Activities          
Redemption of Class A ordinary shares   117,744,389    
-
 
Extension contribution deposit into the Trust Account   (480,000)   
-
 
Net cash provided by investing activities   117,264,389    
-
 
Cash Flows from Financing Activities          
Redemption of Class A ordinary shares   (117,744,389)   
-
 
Proceeds from Promissory note – extension loan   480,000    
-
 
Due to related party   15,000    
-
 
Proceeds from Promissory note – working capital loan   177,055    
-
 
Net cash used in financing activities   (117,072,334)   
-
 
           
Net decrease in cash   (11,439)   (701,620)
Cash - beginning of period   13,372    966,695 
Cash - end of period  $1,933   $265,075 
           
Supplemental disclosure of noncash investing and financing activities:          
Remeasurement of Class A ordinary shares to redemption value  $5,203,283   $1,309,179 
Extension contribution due from Sponsor  $480,000   $
-
 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

4

 

 

PYROPHYTE ACQUISITION CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

 

Note 1 – Description of Organization, Business Operations, Going Concern and Basis of Presentation

 

Pyrophyte Acquisition Corp. (the “Company”) is a blank check company incorporated in Cayman Islands on February 12, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar Business Combination with one or more businesses (the “Business Combination”). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.

 

As of September 30, 2023, the Company had not yet commenced any operations. All activity for the period from February 12, 2021 (inception) through September 30, 2023 relates to the Company’s formation and the preparation of the initial public offering (the “Initial Public Offering”) described below, and since the Initial Public Offering, the search for a prospective initial business combination. The Company will not generate any operating revenues until after the completion of its initial business combination, at the earliest. The Company generates non-operating income in the form of interest or dividend income on investments from the proceeds derived from the Initial Public Offering.

 

On November 13, 2023, the Company, Sio Silica Corporation, an Alberta corporation (“Sio”), Sio Silica Incorporated, a newly-formed Alberta corporation formed solely for the purpose of engaging in the Proposed Transactions and that is wholly owned by Feisal Somji, a nominee (“Nominee”) of Sio (“Sio Newco”), and Snowbank NewCo Alberta ULC, an Alberta unlimited liability corporation and wholly-owned subsidiary of the Company (“Pyrophyte Newco”) entered into a Business Combination Agreement (“BCA”), subject to terms and conditions.

 

The Company’s sponsor is Pyrophyte Acquisition LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for the Company’s Initial Public Offering was declared effective on October 26, 2021. On October 29, 2021, the Company consummated its Initial Public Offering of 20,125,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units offered, the “Public Shares”), including 2,625,000 additional Units to cover over-allotments (the “Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $201,250,000, and incurring $181,216 in other offering costs, $2,625,000 in upfront underwriting fees and $8,443,750 in deferred underwriting commissions (Note 5).

 

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 10,156,250 warrants (each, a “Private Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10,156,250 (Note 4).

 

Upon the closing of the Initial Public Offering and the Private Placement, $206,281,250 ($10.25 per Unit) of the proceeds of the Initial Public Offering and the sale of the Private Placement Warrants were deposited into a trust account (the “Trust Account”) in the United States at J.P. Morgan Chase Bank, N.A. maintained by Continental Stock Transfer & Trust Company, acting as trustee, to be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any money market funds meeting certain conditions of Rule 2a-7 of the Investment Company Act of 1940, as amended (the “Investment Company Act”), which invest only in direct U.S, government treasury obligations until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below.

 

On April 24, 2023 the Company received shareholder approval to amend its Amended and Restated Memorandum and Articles of Association (the “Charter”) to extend (the “Extension”) the date by which it must complete an initial business combination from April 29, 2023 to April 29, 2024 (the “Extended Date”). As a result of the Extension receiving approval for the Company’s shareholders, the Sponsor agreed to loan the Company an amount equal to the lesser of (i) $0.04 per public share multiplied by the number of public shares then outstanding and (ii) $160,000, for each calendar month until the earlier of the completion of a business combination or the date of the Company’s liquidation, beginning on April 30, 2023 (as discussed in Note 4). In connection therewith, the Company issued a convertible promissory note to the Sponsor with a principal amount up to $1.92 million (see Note 4).

 

The shareholders also approved a proposal to amend the Charter to permit the Company’s board of directors (the “Board”), in its sole discretion, to elect to wind up the Company’s operations on an earlier date than the Extended Date as determined by the Board and included in a public announcement. The shareholders also approved a proposal to amend the Charter to  eliminate the limitation that the Company may not redeem public shares in an amount that would cause the Company’s net tangible assets to be less than $5,000,001 in connection with the Company’s initial business combination. The shareholders also approved a proposal to provide for the right of a holder of the Company’s Class B ordinary shares, par value $0.0001 per share (the “Class B Ordinary Shares”), to convert into Class A ordinary shares (the “Class A ordinary shares”), par value $0.0001 per share, on a one-for-one basis prior to the closing of an initial business combination at the election of the holder.

 

5

 

 

In connection with the vote to approve the Extension, the holders of 11,151,163 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.56 per share, for an aggregate redemption amount of approximately $118 million. In addition, on April 28, 2023, holders of 5,031,250 Class B Ordinary Shares elected to convert such shares into Class A Ordinary Shares on a one-for-one basis for no consideration.

 

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The New York Stock Exchange rules provide that the Business Combination must occur with one or more target businesses that together have an aggregate fair market value equal to at least 80% of the balance in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the signing a definitive agreement to enter a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination.

 

The Company will provide its holders of the outstanding Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholders meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with an initial business combination, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which public shareholders may seek to redeem their shares, regardless of whether they vote for or against a Business Combination. The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 either immediately prior to or upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination.

 

If the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s amended and restated memorandum and articles of associationprovides that, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from seeking redemption rights with respect to 15% or more of the Public Shares without the Company’s prior written consent.

 

The Public Shareholders will be entitled to redeem their shares for a pro rata portion of the amount then in the Trust Account (initially $10.25 per share, plus any pro rata interest or dividend earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Shareholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the representative of the underwriter (as discussed in Note 5). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. These shares of Class A ordinary share were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”

 

If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its amended and restated memorandum and articles of association, offer such redemption pursuant to the tender offer rules of the Securities and Exchange Commission (the “SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination.

 

6

 

 

The Company’s initial shareholders agreed (a) to vote its Founder Shares (as defined in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination, (b) not to propose an amendment to the Company’s amended and restated memorandum and articles of association with respect to the Company’s pre-Business Combination activities prior to the consummation of a Business Combination unless the Company provides dissenting Public Shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment; (c) not to redeem any shares (including the Founder Shares) and Private Placement Warrants (including underlying securities) into the right to receive cash from the Trust Account in connection with a shareholder vote to approve a Business Combination (or to sell any shares in a tender offer in connection with a Business Combination if the Company does not seek shareholder approval in connection therewith) or a vote to amend the provisions of the amended and restated memorandum and articles of association relating to shareholders’ rights of pre- Business Combination activity and (d) that the Founder Shares and Private Placement Warrants (including underlying securities) shall not participate in any liquidating distributions upon winding up if a Business Combination is not consummated. However, the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares purchased during or after the Initial Public Offering if the Company fails to complete its Business Combination.

 

If the Company is unable to complete a Business Combination by the Extended Date, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest or dividend earned on the funds held in the Trust Account, which interest or dividend shall be net of taxes payable and $100,000 of interest or dividend to pay dissolution expenses, divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirement of applicable law. The representative of the underwriter agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.25).

 

The Sponsor agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.25 per public share and (ii) the actual amount per public share held in the Trust Account as of the day of liquidation of the Trust Account, if less than $10.25 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations. None of the Company’s officers or directors will indemnify the Company for claims by third parties including, without limitation, claims by vendors and prospective target businesses.

 

Risk and Uncertainties

 

The credit and financial markets have experienced extreme volatility and disruptions due to the current conflict between Ukraine and Russia. The conflict is expected to have further global economic consequences, including but not limited to the possibility of severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in inflation rates and uncertainty about economic and political stability. In addition, the United States and other countries have imposed sanctions on Russia which increases the risk that Russia, as a retaliatory action, may launch cyberattacks against the United States, its government, infrastructure and businesses. Any of the foregoing consequences, including those we cannot yet predict, may cause our business, financial condition, results of operations and the price of our ordinary shares to be adversely affected.

 

7

 

 

Emerging Growth Company

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

 

Liquidity and Capital Resources and Going Concern

 

As of September 30, 2023, the Company had $1,933 in cash and no cash equivalents. Further, the Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. If the Company’s estimates of the costs of identifying a target business, undertaking in-depth due diligence, and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to an initial business combination. The liquidation deadline for the Company is also within the next twelve months if an initial Business Combination is not consummated. The Company cannot assure that its plans to consummate an initial Business Combination will be successful.

 

As a result of the above, in connection with the Company’s assessment of going concern considerations in accordance with ASC Subtopic 205-40, “Presentation of Financial Statements – Going Concern,” management has determined that the liquidity conditions and the proximity to liquidation date raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after April 29, 2024. These unaudited condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Note 2 – Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of unaudited condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates are related to the fair value of the warrants.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 

8

 

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair statement of the financial position, operating results and cash flows for the periods presented and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

 

The financial information as of December 31, 2022 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The interim results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any future periods.

 

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. As of September 30, 2023 and December 31, 2022, the Company had cash of $1,933 and $13,372, respectively. The Company did not have any cash equivalents as of September 30, 2023 and December 31, 2022.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. The Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

 

Investments and cash held in Trust Account

 

As of September 30, 2023 and December 31, 2022, the assets held in the Trust Account were held in money market funds and cash. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Interest or dividend income is included in gain on investments held in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information.

 

Net Income Per Ordinary Share

 

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net income per ordinary share is computed by dividing net income by the weighted average number of ordinary share outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and Private Placements to purchase Class A ordinary shares in the calculation of diluted income per share, since their inclusion is contingent on a future event. As a result, diluted income per share is the same as basic income per share for the periods presented.

 

The Company historically has two classes of ordinary shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Upon the conversion event in April 2023 to convert Class B Ordinary shares into Class A Ordinary Shares, the Company now has Class A redeemable and non-redeemable Ordinary Shares. Income and losses are shared pro rata between the redeemable and non-redeemable ordinary shares. Net income per share, basic and diluted for redeemable Class A ordinary shares is calculated by dividing the pro rata allocation of net income to redeemable Class A ordinary shares for the three and nine months ended September 30, 2023 and for the three and nine months ended September 30, 2022 by the weighted average number of redeemable Class A ordinary shares outstanding for the periods. Net income per share basic and diluted for non-redeemable ordinary shares is calculated by dividing the pro rata allocation of net income to non-redeemable ordinary shares or the three and nine months ended September 30, 2023 and for the three and nine months ended September 30, 2022 by the weighted average number of non-redeemable ordinary shares outstanding for the periods. Remeasurement associated with the redeemable shares of Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value.

 

9

 

 

A reconciliation of the net income per ordinary share is as follows.

 

   For The
Three Months
   For The
Three Months
   For The
Nine Months
   For The
Nine Months
 
   Ended   Ended   Ended   Ended 
   September 30,
2023
   September 30,
2022
   September 30,
2023
   September 30,
2022
 
Redeemable Class A Ordinary Shares                    
Numerator: Net Income allocable to Redeemable Class A Ordinary Shares  $872,776   $2,879,870   $2,445,268   $6,102,971 
                     
Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares   8,973,837    20,125,000    13,589,520    20,125,000 
Basic and diluted net income per share, Class A subject to possible redemption
  $0.10   $0.14   $0.18   $0.30 
                     
Non-Redeemable Ordinary Shares                    
Numerator: Net Income allocable to Non-Redeemable Ordinary Shares  $489,329   $719,967   $905,312   $1,525,743 
                     
Denominator: Weighted Average Share Outstanding, Non-Redeemable Ordinary Shares   5,031,250    5,031,250    5,031,250    5,031,250 
Basic and diluted net income per share, non-Redeemable ordinary shares
  $0.10   $0.14   $0.18   $0.30 

 

Class A Ordinary Shares Subject to Possible Redemption

 

All of the Class A ordinary shares sold as part of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s amended and restated memorandum and articles of association. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class A ordinary shares have been classified outside of permanent equity.

 

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid in capital and accumulated deficit.

 

The reconciliation of Class A ordinary shares subject to possible redemption as of September 30, 2023 and December 31, 2022 is as follows:

 

    Shares     Amount  
Class A ordinary shares subject to possible redemption at December 31, 2021     20,125,000     $ 206,281,250  
Remeasurement of Class A ordinary shares to redemption value           3,269,935  
Class A ordinary shares subject to possible redemption at December 31, 2022     20,125,000     $ 209,551,185  
Remeasurement of Class A ordinary shares to redemption value           5,203,283  
Extension contribution due from Sponsor    

     

480,000

 
Redemption of Class A ordinary shares     (11,151,163 )     (117,744,389 )
Class A ordinary shares subject to possible redemption at September 30, 2023     8,973,837     $ 97,490,079  

 

10

 

 

Fair Value Measurements

 

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.

 

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

 

  Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

  Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

  Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

 

Fair Value of Financial Instruments

 

As of September 30, 2023 and December 31, 2022, the carrying values of cash, accounts payable, and accrued expenses, which qualify as financial instruments under the FASB ASC 820, “Fair Value Measurements and Disclosures,” approximate the carrying amounts represented in the balance sheets.

 

The fair value of warrants issued in connection with the Initial Public Offering were initially measured at fair value using a Monte Carlo simulation model for the Public Warrants and Private Placement Warrants. As of September 30, 2023 and December 31, 2022, the fair value of the Public Warrants are now valued based on the listed market price of the Public Warrants since they began trading on December 17, 2021. As of September 30, 2023 and December 31, 2022, the fair value of the Private Placement Warrants were measured by reference to the trading price of the Public Warrants, which is considered to be a Level 2 fair value measurement.

 

Offering Costs

 

Offering costs consist of legal, accounting, underwriting and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Upon the completion of the Initial Public Offering, the offering costs were allocated using the relative fair values of the company ordinary shares and its warrants. The costs allocated to warrants were recognized in other expenses and those related to the Company’s ordinary shares were charged to temporary equity.

 

Derivative Instruments

 

The Company does not use derivative instruments to hedge its exposures to cash flow, market, or foreign currency risks. Management evaluates all of the Company’s financial instruments, including issued warrants to purchase its Class A ordinary shares, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

 

The Company determined that the conversion option embedded in its Promissory Note – Extension Loan and the Promissory Note – Working Capital (“Promissory Notes”) should be bifurcated and accounted for as a derivative in accordance with ASC 815. However, the exercise price of the underlying warrants was greater than the closing price of the Company’s Class A ordinary shares as of September 30, 2023, and when the Promissory Notes were drawn on. The Company believes that the likelihood of the Sponsor’s exercise of the option to convert the Promissory Notes to warrants is de minimis. As a result, the Company recorded zero liability related to the conversion option on the Promissory Notes. As of September 30, 2023, $480,000 has been drawn on the Promissory Note – Extension Loan and $171,055 was outstanding on the Promissory Note – Working Capital.

 

11

 

 

The Company issued 10,062,500 Public warrants to purchase Class A ordinary shares to investors in the Company’s Initial Public Offering and simultaneously issued 10,156,250 Private Placement Warrants. All of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, we recognize the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to re- measurement at each balance sheet date until exercised, and any change in fair value is recognized in the statements of operations.

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.

 

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties for the three and nine months ended September 30, 2023 and September 30, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

 

The Company is considered an exempted Cayman Islands Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the periods presented.

 

Recent Accounting Pronouncements

 

The Company’s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statement.

 

Revisions To Prior Period Financial Statements

 

In the third quarter of 2023, the Company identified an error that resulted from the lack of recognizing contributions for the second and third months of the Extension period in its calculation of Class A ordinary shares subject to possible redemption as of June 30, 2023. This error led to an understatement of Class A ordinary shares subject to possible redemption and extension contribution due from Sponsor by $320,000. The understatement of these balances did not impact the Company’s cash position as of June 30, 2023, and have less than 0.5% impact on the Company’s investments held in Trust Account balance as of June 30, 2023.

 

12

 

 

The Company evaluated the materiality of the error described above from a qualitative and quantitative perspective. Based on such evaluation taking into account the requirements of SEC Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (“SAB 108”), the Company concluded that the correction would not be material to the financial position or results of operations for the six months ended June 30, 2023. The unaudited condensed financial statements as of June 30, 2023 is revised as follows:

 

   As of June 30, 2023 
Condensed Balance Sheet  As
previously
reported
   Adjustments   As revised 
Extension contribution due from Sponsor  $
-
   $320,000   $320,000 
Total current assets   166,689    320,000    486,689 
Total assets   95,730,675    320,000    96,050,675 
                
Class A ordinary shares subject to possible redemption   95,463,977    320,000    95,783,977 
Per share price of Class A ordinary shares subject to possible redemption   10.64    0.03    10.67 
Total Liabilities, Ordinary Shares Subject to Possible Redemption, and Shareholders’ Deficit   95,730,675    320,000    96,050,675 

 

 

   As of June 30, 2023 

Condensed Statements of Changes in Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit

  As
previously
reported
   Adjustments   As revised 
Extension contribution due from Sponsor  $
-
   $320,000   $320,000 
Balance as of June 30, 2023 of Class A ordinary shares subject to possible redemption   95,463,977    320,000    95,783,977 

 

 

   As of June 30, 2023 
Condensed Statements of Cash Flows  As
previously
reported
   Adjustments   As revised 
Non cash investing and financing activities:            
Extension contribution due from Sponsor  $
               -
   $320,000   $320,000 
                

 

Notes to Condensed Financial Statements  As of June 30, 2023 
   As
previously
reported
   Adjustments   As revised 
Note 2 — Summary of Significant Accounting Policies            
Class A ordinary shares subject to possible redemption rollforward            
Extension contribution due from Sponsor  $
-
   $320,000   $320,000 
Class A ordinary shares subject to possible redemption at June 30, 2023   95,463,977    320,000    95,783,977 

 

Note 3 – Initial Public Offering

 

Pursuant to the Initial Public Offering, the Company sold 20,125,000 Units at a purchase price of $10.00 per Unit. Each Unit consists of one share of Class A ordinary shares and one-half of one redeemable warrant (“Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of Class A ordinary shares at an exercise price of $11.50 per share.

 

Note 4 – Related Party Transactions

 

Class B Founder Shares

 

On February 24, 2021, the Sponsor paid $25,000, or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001 (the “Founder Shares”). Up to 750,000 Founder Shares were subject to forfeiture by the Sponsor depending on the extent to which the underwriter’s over-allotment option was exercised. At the close of the Initial Public Offering, the underwriter exercised its overallotment option in full and these Founder Shares were no longer subjected to forfeiture as of October 29, 2021.

   

13

 

 

On September 29, 2021, the Sponsor effected a surrender of 718,750 Class B ordinary shares to the Company for no consideration, resulting in an aggregate of 5,031,250 of Class B ordinary shares outstanding. Prior to the initial investment in the Company of $25,000 by the Sponsor, we had no assets, tangible or intangible. The per share purchase price of the Founder Shares was determined by dividing the amount of cash contributed to the Company by the aggregate number of Founder Shares issued.

 

Private Placement Warrants

 

Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 10,156,250 Private Placement Warrants at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10,156,250.

 

Each warrant is exercisable to purchase one Class A ordinary share at a price of $11.50 per share. Certain proceeds from the sale of the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirement of applicable law) and the Private Placement Warrants will expire worthless.

 

Promissory Note

 

The Sponsor agreed to loan the Company an aggregate of up to $300,000 to be used for a portion of the expenses of the Initial Public Offering. The promissory note loan was non-interest bearing, unsecured and due at the earlier of December 31, 2021 or the closing of the Initial Public Offering. Upon the consummation of the Initial Public Offering, all outstanding balance under the promissory note was paid in full. As of September 30, 2023 and December 31, 2022, the Company can no longer draw on this promissory note.

 

Convertible Promissory Notes

 

Promissory Note – Extension Loan

 

In connection with the Extension, the Sponsor agreed to loan the Company an amount equal to the lesser of (i) $0.04 per public share multiplied by the number of public shares then outstanding and (ii) $160,000, for each calendar month beginning on April 30, 2023 until the earlier of (i) the completion of a business combination and (ii) the Company’s liquidation (each, a “Contribution”).

 

In connection with the first Contribution, on May 4, 2023, the Company issued a convertible promissory note to the Sponsor with a principal amount up to $1.92 million for working capital expenses (as discussed in Note 1). The convertible promissory note bears no interest and is repayable in full upon the earlier of the consummation of the Company’s initial business combination, or the liquidation of the Company. If the Company does not consummate an initial business combination within the Combination Period, the convertible promissory note will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven. Upon maturity, the outstanding principal of the convertible promissory note may be converted into warrants identical to the Private Placement capital warrants, at a price of $1.00 per warrant, at the option of the Sponsor. As of September 30, 2023, the Sponsor has advanced $480,000 to the Company representing extension contribution through June 30, 2023.

 

The Company determined that the conversion option should be bifurcated and accounted for as a derivative in accordance with ASC 815. However, the exercise price of the underlying warrants was greater than the closing price of the Company’s Class A ordinary shares as of September 30, 2023, and when the convertible promissory note was drawn on. The Company believes that the likelihood of the Sponsor’s exercise of the option to convert the convertible promissory note to warrants is de minimis. As a result, the Company recorded zero liability related to the conversion option.

  

14

 

 

Extension Contribution Due from Sponsor

 

In connection with the Extension, the Sponsor is obligated to fund the Trust Account with $160,000 monthly until earlier of the completion of a business combination or Company’s liquidation. As of September 30, 2023, $480,000 representing the extension contribution for the fourth, fifth, and sixth months of the Extension is due from Sponsor. The Sponsor made a deposit of $160,000 into the Trust Account on November 20, 2023, representing the deposit for the fourth month of the Extension.

 

Promissory Note – Working Capital Loan

 

In order to finance transaction costs in connection with an initial business combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes an initial business combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. In the event that an initial business combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of an initial business combination or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into Private Placement Warrants of the post-initial business combination entity at a price of $1.00 per warrant. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of September 30, 2023 and December 31, 2022, the Company had $171,055 and $0 outstanding under the Working Capital Loans.

 

Administrative Support Agreement

 

Commencing on the date of the Initial Public Offering, the Company has paid the Sponsor $15,000 per month for office space, utilities, secretarial and administrative support services provided to the members of the Company’s management team, which included payment of $10,000 per month to our former Chief Financial Officer and Executive Vice President of Business Development. Upon completion of the initial business combination or the Company’s liquidation, the Company will cease paying these monthly fees. On July 1, 2022 the Company amended the administrative support agreement with the Sponsor from $15,000 per month to $5,000 per month. The Company incurred $45,000 and $105,000 for the nine months ended September 30, 2023 and September 30, 2022, respectively, in Sponsor administrative fees. For the three months ended September 30, 2023 and 2022, the Company incurred $15,000 and $30,000, respectively.

 

For the nine months ended September 30, 2023 and September 30, 2022, the Company reimbursed management $15,626 and $85,325, respectively, for expenses related to acquisition activities.

 

Due from Related Party

 

As of September 30, 2023 and December 31, 2022, the Company was due $0 and $49,500, respectively, from the Sponsor for an overpayment of reimbursable expenses and administrative support fees.

 

Due to Related Party

 

As of September 30, 2023 and December 31, 2022, the Company has an outstanding of $15,000 and $0 respectively due to the Sponsor for administrative support services.

 

Note 5 – Commitments & Contingencies

 

Registration and Shareholder Rights

 

The holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of working capital loans, if any (and any Class A ordinary share issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the working capital loans), will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to the consummation of the Initial Public Offering. These holders will be entitled to certain demand and “piggyback” registration rights. However, the registration rights agreement will provide that we will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable lock- up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

15

 

 

Underwriting Agreement

 

The Company granted the underwriter a 45-day option to purchase up to 2,625,000 additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. The underwriter fully exercised the option on October 29, 2021.

 

The underwriter was entitled to a cash underwriting discount of 1.5% of the gross proceeds of the Initial Public Offering, or $2,625,000 in the aggregate, which was paid upon closing of the Initial Public Offering. In addition, the underwriter was entitled to a deferred fee of 4.0% of the gross proceeds of the Initial Public Offering. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

 

Investment Advisory Agreement

 

On November 5, 2021, the Company entered into an investment advisory agreement with Clean Energy Associates, LLC (“Clean Energy”), pursuant to which Clean Energy will serve as an investment advisor in connection with the Company’s initial Business Combination. If the Company enters into a letter of intent with a potential target that has been introduced to it by Clean Energy, it shall pay Clean Energy a cash success fee of $40,000. Clean Energy shall also be paid a retainer of up to $40,000. This agreement was subsequently terminated on January 14, 2023. As of and for the period ended September 30, 2023 and December 31, 2022 there were no amounts incurred and accrued for Clean Energy.

 

Financial Advisory Agreements

 

On March 28, 2022 the Company engaged UBS Securities LLC (“UBS”), the underwriter in the Initial Public Offering, as a financial advisor and capital markets advisor in connection with a specified de-SPAC transaction. The Company will pay UBS a cash fee for such services upon the consummation of such transaction in an amount equal to $3,000,000. The letter of intent related to this agreement expired on July 1, 2022 and as such rendered this agreement void and no future accrual or expense will be booked. The agreement provided for up to $25,000 in reimbursable fees to UBS and as of the expiration date of the agreement, there are no reimbursable fees incurred by the Company.

 

On November 8, 2021 the Company engaged Atrium Partners A/S (“Atrium”), as a financial advisor in relation to the potential acquisition of one or more companies in a specific industry. The Company will pay Atrium a cash fee for such services upon the consummation of such transaction in an amount equal to 1% of the enterprise value of the target company at the time of closing. This agreement was terminated in February 2022. As of and for the three months ended September 30, 2023 and 2022, the Company did not incur or pay any fees related to the Atrium agreement.

 

On September 26, 2022 the Company reengaged Atrium, as a financial advisor in relation to the potential acquisition of one or more companies in a specific industry under the term of the new agreement the Company will pay Atrium a weekly retainer for the weeks they are engaged in the acquisition efforts as well as a success fee for such services upon the consummation of such transaction in an amount equal to 1% of the enterprise value of the target company at the time of closing. On November 6, 2022, the agreement was terminated and the Company has no further obligation under such agreement. For the nine months ended September 30, 2023 and 2022 there were $0 and $45,225, respectively, of amounts, as well as 0.75% of any additionally raised capital to fund such transaction, incurred for Atrium under the terms of the new agreement. No expenses were incurred in the three months ended September 30, 2023 and 2022.

 

In June 2023, the Company re-engaged UBS as its exclusive capital markets advisor for potential business combination. In October 2023, an amended agreement was executed between the Company and UBS such that the Company will pay UBS a cash fee for such services upon the consummation of such transaction in an amount equal to $5,000,000, subject to adjustment. The exclusivity agreement will lapse six months from the effective date of the agreement unless terminated earlier pursuant to the agreement.

 

Note 6 — Derivative Warrant Liabilities

 

The Company accounted for the 20,218,750 Warrants issued in connection with the Initial Public Offering (the 10,062,500 of Public Warrants and the 10,156,250 of Private Placement Warrants) in accordance with the guidance contained in ASC 815- 40 Derivatives and Hedging — Contracts in Entity’s Own Equity. Such guidance provides that, because the Warrants do not meet the criteria for equity treatment thereunder, each Warrant must be recorded as a liability. Accordingly, the Company classifies each warrant as a liability at its fair value. This liability is subject to re-measurement at each balance sheet date. With each such re-measurement, the Warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations.

 

16

 

 

Additionally, certain adjustments to the settlement amount of the Private Placement Warrants are based on a variable that is not an input to the fair value of a “fixed-for-fixed” option as defined under ASC 815-40, and thus the Private Placement Warrants are not considered indexed to the Company’s own stock and not eligible for an exception from derivative accounting.

 

The accounting treatment of derivative financial instruments requires that the Company record a derivative liability upon issuance of the warrants at the closing of the Initial Public Offering. Accordingly, the Company expects to classify each warrant as a liability at its fair value. The Public Warrants will be allocated a portion of the proceeds from the issuance of the Units equal to its fair value determined with the assistance of a professional independent valuation firm. The warrant liability is subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statements of operations. The Company will reassess the classification of the warrants at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification.

 

Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable 30 days after the completion of a Business Combination provided that the Company has an effective registration statement under the Securities Act covering the Class A ordinary share issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or holders are permitted to exercise their warrants on a cashless basis under certain circumstances as a result of (i) the Company’s failure to have an effective registration statement by the 60th business day after the closing of the initial business combination or (ii) a notice of redemption described under “Redemption of warrants when the price per share of Class A ordinary share equals or exceeds $10.00”). The Company has agreed that as soon as practicable, but in no event later than 20 business days after the closing of its initial business combination, the Company will use its commercially reasonable efforts to file with the SEC and have an effective registration statement covering the Class A ordinary share issuable upon exercise of the warrants and will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of the Company’s initial business combination and to maintain a current prospectus relating to those Class A ordinary share until the warrants expire or are redeemed. If the shares issuable upon exercise of the warrants are not registered under the Securities Act in accordance with the above requirements, the Company will be required to permit holders to exercise their warrants on a cashless basis. However, no warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available. Notwithstanding the above, if the Company’s Class A ordinary share are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, it will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

 

The warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if (x) the Company issues additional Class A ordinary share or equity-linked securities for capital raising purposes in connection with the closing of the initial business combination at an issue price or effective issue price of less than $9.20 per share of Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest or dividend thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions) and (z) the volume weighted average trading price of Class A ordinary share during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices described under “Redemption of warrants for Class A ordinary share” and “Redemption of warrants for cash” will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued Price, respectively.

 

17

 

 

The Private Placement Warrants are identical to the Public Warrants, except that, so long as they are held by the Sponsor or its permitted transferees, (i) they will not be redeemable by the Company, (ii) they (including the Class A ordinary share issuable upon exercise of these warrants) may not, subject to certain limited exceptions, be transferred, assigned or sold by the Sponsor until 30 days after the completion of the initial business combination, (iii) they may be exercised by the holders on a cashless basis and (iv) are subject to registration rights.

 

If a tender offer, exchange or redemption offer shall have been made to and accepted by the holders of the Class A ordinary share and upon completion of such offer, the offeror owns beneficially more than 50% of the outstanding Class A ordinary share the holder of the warrant shall be entitled to receive the highest amount of cash, securities or other property to which such holder would actually have been entitled as a shareholder if such warrant had been exercised, accepted such offer and all of the Class A ordinary share held by such holder had been purchased pursuant to the offer. If less than 65% of the consideration receivable by the holders of the Class A ordinary share in the applicable event is payable in the form of common equity in the successor entity that is listed on a national securities exchange or is quoted in an established over-the-counter market, and if the holder of the warrant properly exercises the warrant within thirty days following the public disclosure of the consummation of the applicable event by the Company, the warrant price shall be reduced by an amount equal to the difference (but in no event less than zero) of (i) the warrant price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined in the warrant agreement) minus (B) the value of the warrant based on the Black-Scholes Warrant Value for a Capped American Call on Bloomberg Financial Markets.

 

Redemption of warrants when the price per share of Class A ordinary share equals or exceeds $18.00: Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):

 

in whole and not in part;

 

at a price of $0.01 per warrant;

 

upon a minimum of 30 days’ prior written notice of redemption; and

 

if, and only if, the last reported sale price (the “closing price”) of Class A ordinary share equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities — Warrants — Public Warrants — Redemption Procedures — Anti-dilution Adjustments”) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders.

 

The Company will not redeem the warrants as described above unless an effective registration statement under the Securities Act covering the Class A ordinary share issuable upon exercise of the warrants is effective and a current prospectus relating to those Class A ordinary share is available throughout the 30-day redemption period. Any such exercise would not be on a cashless basis and would require the exercising warrant holder to pay the exercise price for each warrant being exercised.

 

Redemption of warrants when the price per share of Class A ordinary share equals or exceeds $10.00: Once the warrants become exercisable, the Company may redeem the outstanding warrants:

 

  in whole and not in part;

 

  at a price of $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table set forth under “Description of Securities — Warrants — Public Warrants” based on the redemption date and the “fair market value” of Class A ordinary share (as defined below) except as otherwise described in “Description of Securities — Warrants — Public Warrants”; and;

 

18

 

 

  if, and only if, the closing price of Class A ordinary share equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities — Warrants — Public Warrants — Redemption Procedures — Anti-dilution Adjustments”) for any 20 trading days within the 30-trading day period ending three trading days before we send the notice of redemption to the warrant holders; and

 

  if the closing price of the Class A ordinary share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading “Description of Securities — Warrants — Public Warrants — Redemption Procedures — Anti-dilution Adjustments”), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described above.

 

In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

 

Note 7 – Shareholders’ Deficit

 

Preference shares - The Company is authorized to issue 1,000,000 shares of preference shares, par value $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September 30, 2023 and December 31, 2022, there were no shares of preference shares issued or outstanding.

 

Class A ordinary shares - The Company is authorized to issue 200,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of September 30, 2023 and December 31, 2022, there were no Class A ordinary shares issued or outstanding (excluding 8,973,837 and 20,125,000 Class A ordinary shares subject to possible redemption, respectively).

 

Class B ordinary shares - The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. On September 29, 2021, the Sponsor surrendered 718,750 Founder Shares to us for cancelation for no consideration, resulting an aggregate of 5,031,250 Founder Shares outstanding. On April 24, 2023, in connection with the Company’s extraordinary meeting, passed an amendment to the Company’s Charter allowing Class B shareholders the right to convert their shares into Class A ordinary shares at the election of the holder. As a result of this amendment, all Class B ordinary shareholders elected to convert their shares into Class A ordinary shares thus reducing the number of Class B ordinary shares issued and outstanding to zero. As of September 30, 2023 and December 31, 2022, there were 0 and 5,031,250 Class B ordinary shares issued and outstanding, respectively.

 

Holders of the Class A ordinary shares and holders of the Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders, except as required by law or stock exchange rule.

 

19

 

  

Note 8 – Fair Value Measurements

 

The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2023 by level within the fair value hierarchy:

 

   Level 1   Level 2   Level 3 
Assets:            
Investments and cash held in trust account  $97,110,088   $
   $
 
Liabilities:               
Public warrants  $
   $654,062   $
 
Private placement warrants   
    660,156    
 

 

The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 by level within the fair value hierarchy:

 

   Level 1   Level 2   Level 3 
Assets:            
Investments and cash held in trust account  $209,651,193   $
   $
 
Liabilities:               
Public warrants  $754,687   $
   $
 
Private placement warrants   
    761,719    
 

 

The fair value of the Public Warrants issued in connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation model. The fair value of Public Warrants issued in connection with the Initial Public Offering have been measured based on the listed market price of such warrants, a Level 1 measurement, since December 17, 2021, which was the date the Public Warrants detached from the Units. The close price of the Public Warrants on the New York Stock Exchange was used as the primary input to the fair value of the Public Warrants as of each relevant date subsequent to December 17, 2021. The measurement of the Public Warrants after the detachment of the Public Warrants from the Units is classified as Level 1 due to the use of an observable market quote in an active market. The subsequent measurements of the Private Placement Warrants after the detachment of the Public Warrants from the Units are classified as Level 2 due to the use of an observable market quote for a similar asset in an active market.

 

There was zero trading volume of the Company’s public warrants on September 30, 2023, a level 2 measurement. The fair value of the Private Placement Warrants has subsequently been measured by reference to the trading price of the Public Warrants, which is considered to be a Level 2 fair value measurement.

 

Transfers to/from Levels 1, 2, and 3 are recognized at the end of the period. The public warrants were transferred from level 1 to level 2 for the period ended June 30, 2023 due to zero trading volume on June 30, 2023. For the nine months ended September 30, 2022, the private warrants transferred from level 3 to level 2 as the Company referenced to the price of the public warrant rather than a level 3 input. There were no other transfers to/from any level for the three and nine months ended September 30, 2023 and 2022.

 

Note 9 – Subsequent Events

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date the unaudited condensed financial statements were issued. The Company did not identify any other subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements, excluding the items discussed below.

 

On October 26, 2023, the Company and UBS executed an amendment to its engagement letter in its capacity as exclusive capital markets advisor in connection with the Sio Business Combination to update fees payable to UBS in connection therewith to $5,000,000, subject to adjustment, which will be paid upon the consummation of an initial business combination.

 

On November 13, 2023, the Company, Sio Silica Corporation, an Alberta corporation (“Sio”), Sio Silica Incorporated, a newly-formed Alberta corporation formed solely for the purpose of engaging in the Proposed Transactions and that is wholly owned by Feisal Somji, a nominee (“Nominee”) of Sio (“Sio Newco”), and Snowbank NewCo Alberta ULC, an Alberta unlimited liability corporation and wholly-owned subsidiary of the Company (“Pyrophyte Newco”), entered into a Business Combination Agreement (the “Business Combination Agreement”). See “Management’s Discussion and Analysis of Financial Condition and Results of Operation--Recent Developments--Proposed Business Combination” for more information.

 

On November 20, 2023, in connection with the Company extension arrangement, the Sponsor advanced $160,000 to the Company as a contribution for one additional month of extension. These funds were deposited into the Trust Account pursuant to the agreement and not available for the Company working capital needs.

 

20

 

  

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

References in this Quarterly Report on Form 10-Q (the “Quarterly Report”) to “we,” “us,” the “Company” or “Pyrophyte” refer to Pyrophyte Acquisition Corp. References to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to Pyrophyte Acquisition LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations thereof and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company annual report for December 31, 2022 on Form 10-K filed with the SEC on April 12, 2023. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

 

Overview

 

We are a blank check company formed under the laws of Cayman Islands on February 12, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses. While we may pursue an initial business combination opportunity in any industry or sector, we will seek targets around the world that we believe are market leaders in facilitating energy transition toward decarbonization and sustainable use of energy and natural resources, and are positioned to generate long-term value and growing cash flows. In particular, we will seek to identify companies provide the necessary products, equipment, services and technologies to support the energy transition, without the need to have their business rely solely on a single type of technology. We believe our leadership team’s broad and diverse global network of transaction sources and relationships across a wide spectrum of renewable energy sectors will allow us to effectively and efficiently identify and evaluate potential opportunities for our initial business combination.

 

We intend to effectuate our business combination using cash from the proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, and our capital stock, debt or a combination of cash, stock and debt. Our registration statement for the Initial Public Offering became effective on October 26, 2021. We consummated the Initial Public Offering of 20,125,000 Units on October 29, 2021. Each Unit consisted of one Class A ordinary share and one-half of one redeemable warrant, including the issuance of 2,625,000 Units as a result of the underwriter’s exercise of its over-allotment option in full. Each Unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each public warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $201,250,000, and incurred $11,068,750 in underwriting fees (inclusive of $8,443,750 in deferred underwriting fees).

  

21

 

 

Simultaneously with the closing of the Initial Public Offering on October 29, 2021, we completed the closing of the Private Placement of an aggregate 10,156,250 Private Placement Warrants at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10,156,250.

 

Upon the closing of the Initial Public Offering, the over-allotment and the Private Placement, $206,281,250 ($10.25 per unit) of the net proceeds of the sale of the Units in the Initial Public Offering, the over-allotment and the Private Placement were placed in the Trust Account with Continental Stock Transfer & Trust Company acting as trustee and invested in United States government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act, as determined by us, until the earlier of: (i) the completion of a business combination and (ii) the distribution of the Trust Account as described below.

 

On April 24, 2023 we held an extraordinary general meeting (the “EGM”), pursuant to which its shareholders approved an amendment to our amended and restated memorandum and articles of association (the “Charter”) to, among other things, extend the date in which we have to consummate a business combination from April 29, 2023 to April 29, 2024 (the “Extension”) and provide for the conversion of Class B ordinary shares of the Company, par value $0.0001 per share (the “Class B Ordinary Shares”) into Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”) (the “Founder Share Amendment”). In connection with the vote to approve the Extension, the holders of 11,151,163 Class A ordinary shares exercised their right to redeem their shares for cash at a redemption price of approximately $10.56 per share, for an aggregate redemption amount of approximately $118 million.

 

Our management and our board of directors have broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering, the over-allotment and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a business combination.

 

If we have not completed our initial business combination within the Combination Period, we will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest or dividend earned on the funds held in the Trust Account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

 

On April 28, 2023, in connection with the Founder Share Amendment and pursuant to the Charter, the Sponsor elected to convert 5,031,250 Class B Ordinary Shares held by it into Class A Ordinary Shares on a one-for-one basis for no consideration. 

 

Results of Operations

 

We have neither engaged in any operations nor generated any revenues to date. Our only activities since February 12, 2021 (inception) have been organizational activities and those necessary to prepare for the IPO. Following the IPO, we will not generate any operating revenues until after completion of our initial Business Combination. We will generate non-operating income in the form of interest or dividend income on the investments held in the Trust Account. There has been no significant change in our financial or trading position and no material adverse change has occurred since the date of our audited financial statements. After the IPO, we expect to incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses. We expect our expenses to increase substantially after the closing of the IPO.

 

22

 

 

For the three months ended September 30, 2023, we had a net income of $1,362,105, which consists of general and administrative expenses of $547,392 and a loss in fair value of derivative warrant liabilities of $683,395, offset by a gain on investments held in Trust Account of $1,226,102.

 

For the nine months ended September 30, 2023, we had a net income of $3,350,580, which consists of general and administrative expenses of $1,574,892 and a loss in fair value of derivative warrant liabilities of $202,188, offset by a gain on investments held in Trust Account of $4,723,284.

 

For the three months ended September 30, 2022, we had a net income of $3,599,837, which consists of general and administrative expenses of $254,584, offset by a loss in fair value of derivative warrant liabilities of $2,830,625 and a gain on investments held in Trust Account of $1,023,730 and other income of $66.

 

For the nine months ended September 30, 2022, we had a net income of $7,628,714, which consists of general and administrative expenses of $2,034,395, offset by a gain in fair value of derivative warrant liabilities of $8,271,893 and a gain on investments held in Trust Account of $1,391,133 and other income of $83.

 

Liquidity and Capital Resources

 

For the nine months ended September 30, 2023, cash used in operating activities was $203,494. This was made up of a net income of $3,350,580, changes in operating assets and liabilities of $1,371,398, offset by a change in fair value of derivative warrant liabilities of $202,188 and a $4,723,284 gain on investments held in Trust Account.

 

We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest or dividend earned on the Trust Account, excluding deferred underwriting commissions, to complete our initial business combination. We may withdraw interest or dividend from the Trust Account to pay taxes, if any. To the extent that our share capital or debt is used, in whole or in part, as consideration to complete a business combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

 

We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete a business combination.

 

Going Concern Considerations

 

As of September 30, 2023, the Company had $1,933 in cash and no cash equivalents. Further, the Company has incurred and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. Management’s plans to address this need for capital through the Proposed Public Offering. The Company cannot assure that its plans to consummate an initial Business Combination will be successful. If the Company’s estimates of the costs of identifying a target business, undertaking in-depth due diligence, and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to an initial business combination. The liquidation deadline for the Company is also within the next twelve months if an initial Business Combination is not consummated.

 

As a result of the above, in connection with the Company’s assessment of going concern considerations in accordance with ASC Subtopic 205-40, “Presentation of Financial Statements – Going Concern,” management has determined that the liquidity conditions and the proximity to liquidation date raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after April 29, 2024. These unaudited condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Off-Balance Sheet Arrangements

 

We have no obligations, assets or liabilities that would be considered off-balance sheet arrangements as of September 30, 2023 and December 31, 2022. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

  

23

 

 

Commitments and Contractual Obligations

 

For the nine months ended September 30, 2023 and 2022, we did not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities.

 

Registration Rights

 

The holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of working capital loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of working capital loans) are entitled to registration rights pursuant to a registration rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. These holders will be entitled to certain demand and “piggyback” registration rights. We will bear the expenses incurred in connection with the filing of any such registration statements.

 

Underwriting Agreement

 

We granted the underwriter a 45-day option from the final prospectus relating to the Initial Public Offering to purchase up to 2,625,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. On October 29, 2021, the underwriter fully exercised its over-allotment option.

 

Additionally, the underwriter was entitled to a deferred underwriting discount of 4% of the gross proceeds of the base portion of the Public Offering and a deferred underwriting discount of 5.5% of the gross proceeds per over-allotment unit upon the completion of the Company’s initial business combination.

 

Administrative Support Agreement

 

The Company agreed to pay the Sponsor a total of $15,000 per month, commencing on the effective date of the Initial Public Offering, for office space, utilities, secretarial and administrative support services provided to members of the management team, which included payment of $10,000 per month to our former Chief Financial Officer and Executive Vice President of Business Development. Upon completion of the initial business combination or the liquidation, we will cease paying these monthly fees. On July 1, 2022 the Company amended the administrative support agreement with the Sponsor from $15,000 a month to $5,000 a month. The Company incurred $45,000 and $105,000 for the nine months ended September 30, 2023 and September 30, 2022, respectively, in Sponsor administrative fees. For the three months ended September 30, 2023 and 2022, the Company incurred $15,000 and $30,000, respectively.

 

Due to Related Party

 

As of September 30, 2023 and December 31, 2022, the Company has an outstanding of $15,000 and $0 respectively due to the Sponsor for administrative support services.

 

Promissory Note – Extension Loan

 

In connection with the Extension, The Sponsor agreed to loan the Company an amount equal to the lesser of (i) $0.04 per public share multiplied by the number of public shares then outstanding and (ii) $160,000, for each calendar month beginning on April 30, 2023 until the earlier of (i) the completion of a business combination and (ii) the Company’s liquidation. As of September 30, 2023, there were Trust Account deposits in connection with the extension loan, totaling $480,000.

 

24

 

 

In connection with the first Contribution, on May 4, 2023, the Company issued the Note for working capital expenses (as discussed in Note 1). The Note bears no interest and is repayable in full upon the earlier of the consummation of the Company’s initial business combination, or the liquidation of the Company. If the Company does not consummate an initial business combination within the Combination Period, the Note will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven. Upon maturity, the outstanding principal of the Note may be converted into warrants identical to the Private Placement warrants, at a price of $1.00 per warrant, at the option of the Sponsor. As of September 30, 2023, $480,000 has been drawn on the Note.

 

Promissory Note – Working Capital Loan

 

In order to finance transaction costs in connection with an initial business combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required. If the Company completes an initial business combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. In the event that an initial business combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of an initial business combination or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into Private Placement Warrants of the post-initial business combination entity at a price of $1.00 per warrant. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of September 30, 2023 and December 31, 2022, the Company had $171,055 and $0 outstanding under the Working Capital Loans.

 

Other Commitments

 

On November 5, 2021 the Company entered into an investment advisory agreement with Clean Energy Associates, LLC (“Clean Energy”), pursuant to which Clean Energy will serve as an investment advisor in connection with the Company’s initial Business Combination. If the Company enters into a letter of intent with a potential target that has been introduced to it by Clean Energy, it shall pay Clean Energy a cash success fee of $40,000. Clean Energy shall also be paid a retainer of up to $40,000. This agreement was subsequently terminated. For the period ended September 30, 2023 and 2022 there were no amounts incurred and accrued for Clean Energy.

 

On March 28, 2022 the Company engaged UBS, the underwriter in the Initial Public Offering, as a financial advisor and capital markets advisor in connection with a specified de-SPAC transaction. The Company will pay UBS a cash fee for such services upon the consummation of such transaction in an amount equal to $3,000,000. The letter of intent related to this agreement expired on July 1, 2022 and as such rendered this agreement void and no future accrual or expense will be booked. The agreement provided for up to $25,000 in reimbursable fees to UBS and as of the expiration date of the agreement, there are no reimbursable fees incurred by the Company.

 

On November 8, 2021 the Company engaged Atrium as a financial advisor in relation to the potential acquisition of one or more companies in a specific industry. The Company will pay Atrium a cash fee for such services upon the consummation of such transaction in an amount equal to 1% of the enterprise value of the target company at the time of closing. This agreement was terminated in February 2022. For the nine months ended September 30, 2023 and 2022 the Company had incurred and paid $0 and $30,225, respectively, related to the Atrium agreement.

 

On September 26, 2022 the Company reengaged Atrium as a financial advisor in relation to the potential acquisition of one or more companies in a specific industry under the term of the new agreement the Company will pay Atrium a weekly retainer for all weeks they are engaged in the acquisition efforts as well as a cash fee for such services upon the consummation of such transaction in an amount equal to 1% of the enterprise value of the target company at the time of closing. On November 6, 2022, the agreement was terminated and the Company has no further obligation under such agreement. For the nine months ended September 30, 2023 and 2022 there were $0 and $15,000, respectively, of amounts, as well as 0.75% of any additionally raised capital to fund such transaction, incurred for Atrium under the terms of the new agreement. No expenses were incurred in the three months ended September 30, 2023 and 2022.

 

In June 2023, the Company re-engaged UBS as its exclusive capital markets advisor for potential business combination. In October 2023, an amended agreement was executed between the Company and UBS such that The Company will pay UBS a cash fee for such services upon the consummation of such transaction in an amount equal to $5,000,000. The exclusivity agreement will lapse six months from the effective date of the agreement unless terminated earlier pursuant to the agreement.

 

25

 

 

Critical Accounting Policies and Estimates

 

Class A Ordinary Shares Subject to Possible Redemption

 

All of the Class A ordinary shares sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s amended and restated memorandum and articles of association. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class A ordinary shares have been classified outside of permanent equity.

 

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid in capital and accumulated deficit.

 

Net Income Per Ordinary Share

 

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net income per ordinary share is computed by dividing net income by the weighted average number of ordinary share outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and Private Placements to purchase Class A ordinary shares in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted income per share is the same as basic income per share for the period presented.

 

The Company historically has two classes of ordinary shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Upon the conversion event in April 2023 to convert Class B Ordinary shares into Class A Ordinary Shares, the Company now have Class A redeemable and non-redeemable Ordinary Shares. Income and losses are shared pro rata between the redeemable and non-redeemable ordinary shares. Net income per share, basic and diluted for redeemable Class A ordinary shares is calculated by dividing the pro rata allocation of net income to redeemable Class A ordinary shares for the three and nine months ended September 30, 2023 and for the three and nine months ended September 30, 2022 by the weighted average number of redeemable Class A ordinary shares outstanding for the periods. Net income per share basic and diluted for non-redeemable ordinary shares is calculated by dividing the pro rata allocation of net income to non-redeemable ordinary shares or the three and nine months ended September 30, 2023 and for the three and nine months ended September 30, 2022 by the weighted average number of non-redeemable Class A ordinary shares outstanding for the periods. Remeasurement associated with the redeemable shares of Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value.

 

Derivative Instruments

 

The Company does not use derivative instruments to hedge its exposures to cash flow, market, or foreign currency risks. Management evaluates all of the Company’s financial instruments, including issued warrants to purchase its Class A ordinary shares, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

 

The Company issued 10,062,500 Public Warrants to purchase Class A ordinary shares to investors in the Company’s Initial Public Offering and simultaneously issued 10,156,250 Private Placement Warrants. All of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, we recognize the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to re- measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The Company initially utilized a Monte Carlo simulation model to value the Public Warrants and Private Placement Warrants at each balance sheet date, with changes in fair value recognized in the statement of operations. Inherent in pricing models are assumptions and inputs used to arrive the fair value of the Public and Private Placement warrants. The subsequent measurements of the Public Warrants after the detachment of the Public Warrants from the Units on December 17, 2021 were classified as Level 1 due to the use of an observable market quote in an active market under the ticker PHYT.WS. There was zero trading volume of the Company’s public warrants on September 30, 2023, a level 2 measurement. The close price of the Public Warrant was used as the fair value of the Public Warrants as of September 30, 2023. The Private Placement Warrants have a make-whole provision in place, which will enable them to have a fair value similar to Public Warrants as of September 30, 2023.

 

26

 

  

Both the Promissory Note- Extension Loan and Promissory Note- Working Capital (“Promissory Notes”), contain a conversion feature, for which upon maturity, the outstanding principal of the Promissory Notes, at the option of the Sponsor, may be converted into warrants identical to the Private Placement capital warrants. The Company determined that the conversion option should be bifurcated and accounted for as a derivative in accordance with ASC 815. However, the exercise price of the underlying warrants was greater than the closing price of the Company’s Class A ordinary shares as of September 30, 2023, and when the Promissory Notes were drawn on. The Company believes that the likelihood of the Sponsor’s exercise of the option to convert the Promissory Notes to warrants is de minimis. As a result, the Company recorded zero liability related to the conversion option on the Promissory Notes.

 

Investments and cash held in the Trust Account

 

Our portfolio of investments held in the Trust Account is money market funds solely comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities, or a combination thereof. The investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in gain on investments held in Trust Account on the unaudited condensed statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

 

Recent Accounting Standards

 

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s unaudited condensed financial statements.

 

Recent Developments

 

Proposed Business Combination

 

On November 13, 2023, Pyrophyte entered into a business combination agreement (the “Business Combination Agreement” and the transactions contemplated thereby, the “Sio Business Combination”) with Pyrophyte (“Pyrophyte Newco”), pursuant to which, among other things and subject to the terms and conditions contained therein, (i) the Company will transfer by way of continuation from the Cayman Islands to Alberta in accordance with the Cayman Islands Companies Act (as revised) (the “Companies Act”) and continue as an Alberta corporation in accordance with the applicable provisions of the Business Corporations Act (Alberta) (the “ABCA”) (such continuation, the “Domestication”), (ii) following the Domestication, Pyrophyte will amalgamate with Sio Newco (the “SPAC Amalgamation”), with Sio Newco surviving the SPAC Amalgamation (“Pubco”) in accordance with the terms of a Plan of Arrangement (the “Plan of Arrangement”), and (iii) Sio and Pyrophyte Newco will amalgamate (the “Sio Amalgamation” and together with the SPAC Amalgamation, the “Amalgamations”), with Sio surviving the Sio Amalgamation as a wholly-owned subsidiary of Pubco and such entity will continue the business operations currently undertaken by Sio. Pyrophyte’s board of directors has unanimously approved and declared advisable the Business Combination and all the transaction documents therein and resolved to recommend approval of the Sio Business Combination Agreement and related matters by Pyrophyte’s shareholders.

  

Conversion of Securities

 

Domestication

 

Pursuant to the Domestication, Pyrophyte will transfer by way of continuation from the Cayman Islands to Alberta in accordance with the Companies Act and continue as an Alberta corporation in accordance with the applicable provisions of the ABCA. In connection with the Domestication, each then-issued and outstanding Class A Ordinary Share will convert automatically, on a one-for-one basis, into one Class A common share of Pyrophyte (after the Domestication) (the “SPAC Class A Common Shares”) and each of the then-issued and outstanding warrant of Pyrophyte will automatically become a warrant to acquire one SPAC Class A Common Share.

 

27

 

 

SPAC Amalgamation

 

Pursuant to the SPAC Amalgamation, which will take place not later than one business day prior to the closing (the “Closing”) of the Sio Business Combination (the “Closing Date”), but after the Domestication, (i) each then-issued and outstanding SPAC Class A Common Share will be exchanged, on a one-for-one basis, for a Class A common share in the authorized share capital of Pubco (the “Pubco Class A Common Shares”), (ii) each then-issued and outstanding warrant of Pyrophyte will become a warrant to acquire one Pubco Class A Common Share (the “Pubco Warrants”), (iii) each then-issued and outstanding unit of Pyrophyte will be exchanged for a unit of Pubco representing one Pubco Class A Common Share and one-half of one Pubco Warrant (the “Pubco Units”) (each of which will be separated into its component parts in connection with the Closing), (iv) each common share of Sio Newco will be exchanged for one Pubco Class A Common Share, and (v) immediately thereafter, the Pubco Class A Common Share will be purchased by Sio Newco for cash at the price initially paid by such shareholder and immediately cancelled, in each case upon and subject to the terms and conditions set forth in the Business Combination Agreement, the Plan of Arrangement and in accordance with the provisions of applicable law.

 

As a result of the SPAC Amalgamation, all holders of then-issued and outstanding SPAC Class A Common Shares will become holders of Pubco Class A Common Shares.

 

Sio Amalgamation

 

Pursuant to the Sio Amalgamation, on the Closing Date and following the exercise on a cashless basis of all then-issued and outstanding warrants (the “Sio Warrants”) and options of Sio for common shares in the authorized share capital of Sio (the “Sio Common Shares”) in accordance with the Plan of Arrangement (the “Sio Warrant and Option Settlement”), (i) each then-issued and outstanding Sio Common Share (other than any Sio Common Shares issued by Sio to certain investors during the interim period (the “Sio Interim Common Shares”)) will be exchanged for (x) a number of Pubco Class A Common Shares equal to the Sio Common Share Exchange Ratio (as defined below) and (y) a number of Sio Earnout Shares (as defined below) equal to the Sio Earnout Exchange Ratio (as defined below), (ii) each then-issued and outstanding share award to purchase Sio Common Shares (each, a “Sio RSU”) will become exercisable for a number of Pubco Class A Common Shares (rounded down to the nearest whole share) equal to (a) the number of Sio Common Shares subject to the applicable Sio RSU multiplied by (b) the Sio Common Share Exchange Ratio, (iii) any Sio Warrant that is not exercised pursuant to the Sio Warrant and Option Settlement will remain outstanding and will automatically in accordance with its terms become a warrant to acquire Pubco Class A Common Shares, and (iv) each then-issued and outstanding Sio Interim Common Share will be exchanged for a number of Pubco Class A Common Shares equal to (a) the number of then-issued and outstanding Sio Interim Common Shares multiplied by (b) the Sio Common Share Exchange Ratio, in each case upon and subject to the other terms and conditions set forth in the Business Combination Agreement, the Plan of Arrangement and in accordance with the provisions of applicable law.

 

As a result of the Amalgamations, Sio will become a wholly-owned subsidiary of Pubco and will continue the business operations currently undertaken by it. Upon the Closing, the Pubco Class A Common Shares and the Pubco Warrants are expected to trade on the New York Stock Exchange under the symbols “SIOS” and “SIOS WS,” respectively.

 

“Sio Common Share Exchange Ratio” means the quotient obtained by (A) dividing (i) Sio’s valuation of $675,000,000 by (ii) $10.25, and then (B) by further dividing the resulting number of Pubco Class A Common Shares established in (A) above by the sum of (x) the number of Sio Common Shares that are issuable upon the exercise of Sio RSUs that are unexpired, issued and outstanding as of immediately prior to the effective of the Sio Amalgamation (the “Sio Amalgamation Effective Time”), (y) the number of Sio Common Shares issued and outstanding immediately prior to the Sio Amalgamation Effective Time, which shall (1) include any Sio Common Shares issued in connection with the Sio Warrant and Option Settlement and (2) exclude any Sio Interim Common Shares, and (z) the number of Sio Common Shares that are issuable upon the exercise of any issued and outstanding warrants to purchase Sio Common Shares that is not exercised pursuant to the Company Warrant and Option Settlement (“Unexercised Company Warrants”) issued and outstanding as of immediately prior to the Sio Amalgamation Effective Time minus a number of Sio Common Shares with a fair market value equal to the aggregate exercise price (determined with reference to the US dollar to the Canadian dollar exchange rate reported by the Bank of Canada at the close of business on the date that is two (2) business days prior to the Closing) of all such Unexercised Company Warrants if they were so exercised (such sum, the “Fully-Diluted Sio Common Shares”).

 

28

 

 

“Sio Earnout Exchange Ratio” means the quotient obtained by dividing (i) 6,585,366 by (ii) the Fully-Diluted Sio Common Shares.

 

“Sio Earnout Shares” means the pro rata portion of an aggregate of 6,585,366 Pubco Class A Common Shares (without duplication) issued to each shareholder of Sio (other than holders of any Sio Interim Common Shares) pursuant to the Sio Amalgamation and the Business Combination Agreement (the “Earnout”), valued at the deemed issue price of the Pubco Class A Common Shares in connection with the Earnout, which is $10.25 per Pubco Class A Common Share, which Sio Earnout shares are subject to forfeiture in accordance with the terms of the Business Combination Agreement.

 

A copy of the Business Combination Agreement is filed with this Quarterly Report on Form 10-Q as Exhibit 2.1 and is incorporated herein by reference. The foregoing description of the Business Combination Agreement and the Sio Business Combination does not purport to be complete and is qualified in its entirety by reference to the full text of the Business Combination Agreement filed with this Quarterly Report on Form 10-Q. The Business Combination Agreement is included to provide security holders with information regarding its terms. It is not intended to provide any other factual information about Sio, Pyrophyte Newco, Pyrophyte or Sio Newco. In particular, the assertions embodied in representations and warranties by Sio, Pyrophyte Newco, Pyrophyte and Sio Newco contained in the Business Combination Agreement are subject to important qualifications and limitations agreed to by the parties in connection with negotiating such agreement, including being qualified by confidential information in the disclosure schedules provided by the parties in connection with the execution of the Business Combination Agreement, and are subject to standards of materiality applicable to the contracting parties that may differ from those applicable to security holders. The confidential disclosures contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Business Combination Agreement. Moreover, certain representations and warranties in the Business Combination Agreement were used for the purpose of allocating risk between the parties, rather than establishing matters as facts. Accordingly, security holders should not rely on the representations and warranties in the Business Combination Agreement as characterizations of the actual state of facts about Sio, Pyrophyte Newco, Pyrophyte or Sio Newco. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Business Combination Agreement, which subsequent information may or may not be fully reflected in Pyrophyte’s public disclosures.

 

Subscription Agreements

 

Concurrently with the execution of the Business Combination Agreement, Pyrophyte, Sio and Sio Newco entered into subscription agreements with (i) a certain accredited investor (the “Non-Insider PIPE Investor”) and (ii) certain other accredited investors who are existing shareholders of Sio or Pyrophyte (the “Insider PIPE Investors” and, together with the Non-Insider PIPE Investor, the “PIPE Investors”), pursuant to which, among other things, Sio Newco agreed to issue and sell, in a private placement to close concurrently with and conditioned upon the effectiveness of the consummation of the Business Combination, an aggregate of 3,114,258 Pubco Class A Common Shares (the “PIPE Investment”) to the PIPE Investors for an aggregate purchase price equal to $20,122,474.

  

The foregoing description of the PIPE Investment does not purport to be complete and is qualified in its entirety by the terms and conditions of (i) the form of subscription agreement entered into with the Non-Insider PIPE Investors (the “Non-Insider Subscription Agreement”) and (ii) the form of subscription agreement entered into with the Insider PIPE Investors (the “Insider Subscription Agreement” and, together with the Non-Insider Subscription Agreement, the “Subscription Agreements”), as applicable, copies of which are filed as Exhibits 10.1 and 10.2, respectively, hereto and are incorporated by reference herein.

 

Non-Redemption Agreement

 

Concurrently with the execution of the Business Combination Agreement, Pyrophyte and Sio Newco entered into a non-redemption agreement (the “Non-Redemption Agreement”) with a Pyrophyte shareholder with respect to 100,000 SPAC Class A Ordinary Shares held by such shareholder (the “Non-Redemption SPAC Shares”), pursuant to which, among other things, Pyrophyte agreed to issue 58,570 Class A Ordinary Shares to such shareholder in consideration of such shareholder’s commitment not to redeem the Non-Redemption SPAC Shares held by it in connection with the approval of the Business Combination by Pyrophyte’s shareholders (the “Non-Redemption Transaction”).

 

The foregoing description of the Non-Redemption Transaction and the Non-Redemption Agreement does not purport to be complete and is qualified in its entirety by the full text of the Non-Redemption Agreement, a copy of which is filed as Exhibit 10.3 hereto and is incorporated by reference herein.

 

29

 

 

Sponsor Support Agreement

 

Concurrently with the execution of the Business Combination Agreement, the Sponsor, entered into a letter agreement (the “Sponsor Support Agreement”) with Sio, Sio Newco, Pyrophyte and the directors and officers (or otherwise a part of the management team) of Pyrophyte, solely for purposes of amending certain of the terms of the letter agreement signed by them in connection with Pyrophyte’s initial public offering, pursuant to which, among other things, the Sponsor agreed to (i) appear at the extraordinary general meeting of Pyrophyte’s shareholders called to approve the Business Combination (the “Pyrophyte Shareholders Meeting”) or otherwise cause the Covered Shares (as defined below) to be counted as present thereat for the purposes of establishing a quorum, (ii) vote all Class A Ordinary Shares, or any securities convertible into, exercisable or exchangeable for Class A Ordinary Shares, held by it or acquired after the date of the Sponsor Support Agreement (the “Covered Shares”) at the Pyrophyte Shareholders Meeting (or execute and deliver a written consent, if applicable, causing to be voted) (v) in favor of any circumstances upon which a consent or other approval is required under the organizational documents of Pyrophyte or otherwise sought in furtherance of the Business Combination, (w) in favor of the adoption and approval of the Business Combination and each other proposal related to the Business Combination necessary or reasonably requested by Pyrophyte for the consummation of the Business Combination, (x) against any alternative transactions or actions reasonably expected to impede, interfere with, delay, postpone or adversely impact the Business Combination or result in a breach of any covenant, representation or warranty of Pyrophyte under the Business Combination Agreement or result in any of the closing conditions of the Business Combination Agreement not being fulfilled, (y) against any change in the dividend policy or capitalization of, including the voting rights of, any class of shares of Pyrophyte, and (z) against any change in business, management or the board of directors of the Pyrophyte, in each of clause (y) and (z) other than in connection with the Business Combination, (iii) not transfer the Class A Ordinary Shares until the earlier of (a) termination of the Business Combination Agreement and (b) termination of the Sponsor Support Agreement upon mutual written agreement of the parties thereto, (iv) not redeem any Covered Shares owned by it in connection with approval of the Business Combination by Pyrophyte’s shareholders, (v) not transfer any Covered Shares (other than Pubco Class A Common Shares issued upon exercise of any private placement warrants held by the Sponsor) until the earlier of (A) one year after the Closing, (B) the first day the last sale price of Pubco Class A Common Shares equals or exceeds $12.00 per share for any 20 trading days within a 30-day trading period commencing at least 150 days after the Closing or (C) after the Closing, the date on which Pubco completes a liquidation, amalgamation, share exchange or similar transaction resulting in the shareholders of Pubco having the right to exchange their shares for consideration, and (vi) not transfer any private placement warrants (or Pubco Class A Common Shares issued or issuable upon exercise of such warrants) held by it until 30 days after the Closing.

 

In addition, the Sponsor has agreed to subject a number of Class A Ordinary Shares held by it on the date of execution of the Sponsor Support Agreement (“Restricted Owned Shares”) to certain restrictions, to the extent such shares are used to obtain any additional PIPE Financing or other financing arrangements in connection with consummation of the Business Combination; provided that in no event shall the aggregate number of Restricted Owned Shares equal more than 4,025,000 Class A Ordinary Shares (the “Maximum Restricted Owned Shares”). If, prior to the Closing, the sum of all Available Closing Cash raised from the PIPE Investment, any non-redemption agreements (including the Non-Redemption Agreement) and any other cash and cash equivalents of Pyrophyte (including the proceeds of any securities funded in connection with the Closing but excluding, for the avoidance of doubt, (I) the Royalty Agreement Proceeds (as defined in the Business Combination Agreement), (II) proceeds received from any flow-through common shares (other than to the extent that any incentive equity interests are issued in connection with such issuance) and (III) any Indebtedness (as defined in the Business Combination Agreement) funded in connection with the Closing) (collectively, the “SPAC Proceeds”) is less than $70,000,000, then (i) the number of Restricted Owned Shares shall be equal to the actual number of SPAC Class A Ordinary Shares that were used to secure such SPAC Proceeds, up to (but not exceeding) an amount equal to the Maximum Restricted Owned Shares (the “Incentive Owned Shares”), and (ii) a number of SPAC Class A Ordinary Shares owned by Sponsor equal to (x) 4,025,000 minus (y) the number of Incentive Owned Shares shall be automatically forfeited and deemed transferred to Pyrophyte for cancellation for no consideration. If, prior to Closing, the sum of the Available Closing Cash raised from the SPAC Proceeds is equal to or greater than $70,000,000, then the number of Restricted Owned Shares shall be equal to the Incentive Owned Shares.

 

In connection with the Closing, each Restricted Owned Share will be exchanged on a one-for-one basis for Pubco Class A Common Shares pursuant to the Business Combination and the Plan of Arrangement and such shares will be subject to forfeiture or release as follows: (i) half of the Restricted Owned Shares will be released to the Sponsor on the first day that the Trading Price (as defined in the Business Combination Agreement) is at least $12.50, (ii) the other half of the Restricted Owned Shares will be released from forfeiture on the first day that the Trading Price is at least $15.00, in each case during the period commencing on the Closing Date and ending on the date that is three (3) years after the Closing Date (the “End Date”), and (iii) after the End Date, any Restricted Owned Shares that have not been released to the Sponsor pursuant to clauses (i) or (ii) above will be automatically forfeited for no consideration.

 

30

 

 

The foregoing description of the Sponsor Support Agreement is qualified in its entirety by reference to the full text of the Sponsor Support Agreement, a copy of which is included as Exhibit 10.4 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.

 

Sio Securityholder Support Agreements

 

In connection with the execution of the Business Combination Agreement, on November 13, 2023, Pyrophyte, Sio, and certain securityholders of Sio entered into support agreements (the “Sio Securityholder Support Agreements”), pursuant to which, among other things, such shareholders agreed to vote (or cause to be voted) all of their Sio shares and other voting securities of Sio (“Subject Securities”) in favor of the special resolution of Sio shareholders in respect of the Plan of Arrangement, to be considered at Sio’s shareholders meeting to approve the Business Combination. Additionally, such shareholders have agreed, among other things, not to, prior to the Closing, (a) transfer any of their Subject Securities (or enter into any agreement, arrangement or understanding in connection therewith other than pursuant to the Plan of Arrangement), subject to certain customary exceptions, or (b) enter into any voting arrangement that is inconsistent with the Sio Securityholder Support Agreements. Sio covenants in the Business Combination Agreement that it will use commercially reasonable efforts to obtain Sio Securityholder Support Agreements from at least 66 ⅔% of its shareholders as promptly as possible, but in any event, within five days of the execution date of the Business Combination Agreement.

 

The foregoing description of the Sio Securityholder Support Agreements is qualified in its entirety by reference to the full text of the form of Sio Securityholder Support Agreements Support Agreement, a copy of which is included as Exhibit 10.5 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.

 

Trust Account Deposit

 

On November 20, 2023, in connection with the Company extension arrangement, the Sponsor deposited $160,000 into the Trust Account, representing a contribution for the fourth month of extension. The Sponsor intends to make contributions into the Trust Account for the subsequent months of extension by the end of the month of November.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item.

 

Item 4. Controls and Procedures.

 

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Evaluation of Disclosure Controls and Procedures

 

In connection with the preparation of this Quarterly Report, as of September 30, 2023, an evaluation was performed under the supervision and with the participation of our management, including the CEO and CFO, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on such evaluation, our CEO and CFO concluded that, as of September 30, 2023, our disclosure controls and procedures were not effective, due to the material weaknesses in our internal control over financial reporting related to the recording of accruals and the accounting for complex financial instruments, as previously disclosed in our quarterly reports and our Form 10-K. As a result, we performed additional analysis as deemed necessary to ensure that our condensed financial statements were prepared in accordance with GAAP. Accordingly, management believes that the condensed financial statements included in this Quarterly Report present fairly in all material respects our financial position, results of operations and cash flows for the periods presented.

 

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting that occurred during the fiscal quarter ended September 30, 2023 covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

  

31

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 1A. Risk Factors.

 

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on April 12, 2023. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None. 

 

32

 

 

Item 6. Exhibits.

 

Exhibit
Number
  Description
2.1   Business Combination Agreement, dated as of November 13, 2023, by and among Pyrophyte Acquisition Corp., Sio Silica Corporation, Snowbank NewCo Alberta ULC and Sio Silica Incorporated (incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023).
     
10.1   Form of Subscription Agreement with Non-Insider PIPE Investors. (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023)
     
10.2   Form of Subscription Agreement with Insider PIPE Investors. (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023).
     
10.3   Form of Non-Redemption Agreement. (incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023).
     
10.4   Sponsor Support Agreement, dated as of November 13, 2023, by and among Pyrophyte Acquisition LLC, Pyrophyte Acquisition Corp., Sio Silica Corporation, Sio Silica Incorporated and the directors and officers of Pyrophyte Acquisition Corp.(incorporated by reference to Exhibit 10.5 of the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023).
     
10.5   Form of Sio Shareholder Support Agreement (incorporated by reference to Exhibit 10.6 of the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023).
     
31.1*   Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d) to 14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2*   Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d) to 14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1**   Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2**   Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS   Inline XBRL Instance Document.
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.

 

** These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

33

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 20, 2023 PYROPHYTE ACQUISITION CORP.
     
  By: /s/ Bernard J. Duroc-Danner
  Name:  Bernard J. Duroc-Danner
  Title:

Chief Executive Officer and Chairman

(Principal Executive Officer)

     
Dated: November 20, 2023 By: /s/ Sten Gustafson
  Name:  Sten Gustafson
  Title:

Chief Financial Officer and Director

(Principal Financial Officer)

 

 

34

 

 

00-0000000 13589520 20125000 20125000 8973837 0.10 0.14 0.18 0.30 5031250 5031250 5031250 5031250 0.10 0.14 0.18 0.30 0.10 0.14 0.18 0.30 0.10 0.14 0.18 0.30 false --12-31 Q3 0001848756 0001848756 2023-01-01 2023-09-30 0001848756 phyt:UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember 2023-01-01 2023-09-30 0001848756 phyt:ClassAOrdinarySharesParValue00001PerShareMember 2023-01-01 2023-09-30 0001848756 phyt:RedeemableWarrantsEachExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf1150PerShareMember 2023-01-01 2023-09-30 0001848756 2023-11-20 0001848756 2023-09-30 0001848756 2022-12-31 0001848756 us-gaap:RelatedPartyMember 2023-09-30 0001848756 us-gaap:RelatedPartyMember 2022-12-31 0001848756 phyt:ClassAOrdinarySharesSubjectToPossibleRedemptionMember 2023-09-30 0001848756 phyt:ClassAOrdinarySharesSubjectToPossibleRedemptionMember 2022-12-31 0001848756 us-gaap:CommonClassAMember 2023-09-30 0001848756 us-gaap:CommonClassAMember 2022-12-31 0001848756 us-gaap:CommonClassBMember 2023-09-30 0001848756 us-gaap:CommonClassBMember 2022-12-31 0001848756 2023-07-01 2023-09-30 0001848756 2022-07-01 2022-09-30 0001848756 2022-01-01 2022-09-30 0001848756 phyt:CommonClassaSubjectToRedemptionMember 2023-07-01 2023-09-30 0001848756 phyt:CommonClassaSubjectToRedemptionMember 2022-07-01 2022-09-30 0001848756 phyt:CommonClassaSubjectToRedemptionMember 2023-01-01 2023-09-30 0001848756 phyt:CommonClassaSubjectToRedemptionMember 2022-01-01 2022-09-30 0001848756 phyt:NonRedeemableClassBOrdinarySharesMember 2023-07-01 2023-09-30 0001848756 phyt:NonRedeemableClassBOrdinarySharesMember 2022-07-01 2022-09-30 0001848756 phyt:NonRedeemableClassBOrdinarySharesMember 2023-01-01 2023-09-30 0001848756 phyt:NonRedeemableClassBOrdinarySharesMember 2022-01-01 2022-09-30 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2022-12-31 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001848756 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001848756 us-gaap:RetainedEarningsMember 2022-12-31 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2023-01-01 2023-03-31 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001848756 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001848756 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001848756 2023-01-01 2023-03-31 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2023-03-31 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-03-31 0001848756 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001848756 us-gaap:RetainedEarningsMember 2023-03-31 0001848756 2023-03-31 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2023-04-01 2023-06-30 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001848756 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001848756 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001848756 2023-04-01 2023-06-30 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2023-06-30 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-06-30 0001848756 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001848756 us-gaap:RetainedEarningsMember 2023-06-30 0001848756 2023-06-30 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2023-07-01 2023-09-30 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001848756 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001848756 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2023-09-30 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-09-30 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-09-30 0001848756 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001848756 us-gaap:RetainedEarningsMember 2023-09-30 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2021-12-31 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001848756 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001848756 us-gaap:RetainedEarningsMember 2021-12-31 0001848756 2021-12-31 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2022-01-01 2022-03-31 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001848756 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001848756 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001848756 2022-01-01 2022-03-31 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2022-03-31 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-03-31 0001848756 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001848756 us-gaap:RetainedEarningsMember 2022-03-31 0001848756 2022-03-31 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2022-04-01 2022-06-30 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001848756 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001848756 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001848756 2022-04-01 2022-06-30 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2022-06-30 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001848756 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001848756 us-gaap:RetainedEarningsMember 2022-06-30 0001848756 2022-06-30 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2022-07-01 2022-09-30 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001848756 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001848756 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001848756 us-gaap:CommonClassAMember phyt:OrdinarySharesSubjectToPossibleRedemptionMember 2022-09-30 0001848756 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-09-30 0001848756 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-09-30 0001848756 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001848756 us-gaap:RetainedEarningsMember 2022-09-30 0001848756 2022-09-30 0001848756 us-gaap:IPOMember 2021-10-29 0001848756 us-gaap:OverAllotmentOptionMember 2021-10-01 2021-10-29 0001848756 us-gaap:OverAllotmentOptionMember 2021-10-29 0001848756 2021-10-01 2021-10-29 0001848756 2021-10-29 0001848756 us-gaap:PrivatePlacementMember 2023-09-30 0001848756 us-gaap:PrivatePlacementMember 2023-01-01 2023-09-30 0001848756 phyt:BusinessCombinationMember 2023-09-30 0001848756 us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001848756 us-gaap:CommonClassBMember 2023-04-28 0001848756 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-09-30 0001848756 us-gaap:IPOMember 2023-09-30 0001848756 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-01-01 2023-09-30 0001848756 us-gaap:WarrantMember us-gaap:CommonClassAMember 2023-09-30 0001848756 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2023-09-30 0001848756 phyt:ClassAOrdinarySharesSubjectToPossibleRedemptionMember 2023-01-01 2023-09-30 0001848756 phyt:RedeemableClassAOrdinarySharesMember 2023-07-01 2023-09-30 0001848756 phyt:RedeemableClassAOrdinarySharesMember 2022-07-01 2022-09-30 0001848756 phyt:RedeemableClassAOrdinarySharesMember 2023-01-01 2023-09-30 0001848756 phyt:RedeemableClassAOrdinarySharesMember 2022-01-01 2022-09-30 0001848756 phyt:ClassASubjectToPossibleRedemptionMember 2023-07-01 2023-09-30 0001848756 phyt:ClassASubjectToPossibleRedemptionMember 2022-07-01 2022-09-30 0001848756 phyt:ClassASubjectToPossibleRedemptionMember 2023-01-01 2023-09-30 0001848756 phyt:ClassASubjectToPossibleRedemptionMember 2022-01-01 2022-09-30 0001848756 phyt:NonRedeemableClassAOrdinarySharesMember 2023-07-01 2023-09-30 0001848756 phyt:NonRedeemableClassAOrdinarySharesMember 2022-07-01 2022-09-30 0001848756 phyt:NonRedeemableClassAOrdinarySharesMember 2023-01-01 2023-09-30 0001848756 phyt:NonRedeemableClassAOrdinarySharesMember 2022-01-01 2022-09-30 0001848756 2022-01-01 2022-12-31 0001848756 srt:ScenarioPreviouslyReportedMember 2023-06-30 0001848756 srt:RestatementAdjustmentMember 2023-06-30 0001848756 phyt:RevisedMember 2023-06-30 0001848756 srt:ScenarioPreviouslyReportedMember 2023-01-01 2023-06-30 0001848756 srt:RestatementAdjustmentMember 2023-01-01 2023-06-30 0001848756 phyt:RevisedMember 2023-01-01 2023-06-30 0001848756 us-gaap:CommonClassAMember us-gaap:IPOMember 2023-01-01 2023-09-30 0001848756 us-gaap:CommonClassAMember us-gaap:IPOMember 2023-09-30 0001848756 phyt:PublicWarrantsMember us-gaap:CommonClassAMember 2023-09-30 0001848756 us-gaap:CommonClassBMember 2021-02-01 2021-02-24 0001848756 us-gaap:CommonClassBMember 2021-02-24 0001848756 2021-02-01 2021-02-24 0001848756 us-gaap:CommonClassBMember 2021-09-01 2021-09-29 0001848756 us-gaap:CommonClassBMember 2021-09-29 0001848756 2023-04-30 2023-04-30 0001848756 phyt:SponsorMember 2023-05-04 0001848756 2023-05-04 2023-05-04 0001848756 phyt:SponsorMember 2023-01-01 2023-09-30 0001848756 us-gaap:SubsequentEventMember phyt:SponsorMember 2023-11-20 0001848756 us-gaap:IPOMember 2023-01-01 2023-09-30 0001848756 phyt:SponsorMember 2022-07-01 2022-07-01 0001848756 2022-07-01 2022-07-01 0001848756 2021-11-05 0001848756 2021-11-01 2021-11-05 0001848756 2022-03-01 2022-03-28 0001848756 2021-11-08 0001848756 2022-09-26 0001848756 2023-10-31 2023-10-31 0001848756 phyt:PublicWarrantsMember 2023-09-30 0001848756 us-gaap:CommonClassAMember phyt:RedemptionOfWarrantsMember 2023-01-01 2023-09-30 0001848756 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001848756 srt:MinimumMember 2023-01-01 2023-09-30 0001848756 srt:MaximumMember 2023-01-01 2023-09-30 0001848756 phyt:OwnershipMember us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001848756 us-gaap:WarrantMember 2023-09-30 0001848756 phyt:RedemptionOfWarrantsMember 2023-09-30 0001848756 phyt:RedemptionOfWarrantsMember 2023-01-01 2023-09-30 0001848756 us-gaap:FairValueInputsLevel1Member 2023-09-30 0001848756 us-gaap:FairValueInputsLevel2Member 2023-09-30 0001848756 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001848756 us-gaap:FairValueInputsLevel1Member us-gaap:WarrantMember 2023-09-30 0001848756 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember 2023-09-30 0001848756 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2023-09-30 0001848756 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2023-09-30 0001848756 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2023-09-30 0001848756 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2023-09-30 0001848756 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001848756 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001848756 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001848756 us-gaap:FairValueInputsLevel1Member us-gaap:WarrantMember 2022-12-31 0001848756 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember 2022-12-31 0001848756 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2022-12-31 0001848756 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2022-12-31 0001848756 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2022-12-31 0001848756 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2022-12-31 0001848756 us-gaap:SubsequentEventMember 2023-10-26 2023-10-26 0001848756 us-gaap:SubsequentEventMember 2023-11-20 2023-11-20 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Exhibit 31.1

 

CERTIFICATION

PURSUANT TO RULE 13a-14 AND 15d-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

I, Bernard J. Duroc-Danner, certify that:

 

1.I have reviewed this Annual Report on Form 10-Q for the quarter ended September 30, 2023 of Pyrophyte Acquisition Corp.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: November 20, 2023 By: /s/ Bernard J. Duroc-Danner
    Bernard J. Duroc-Danner
    Chief Executive Officer and Director
(Principal Executive Officer)

 

 

Exhibit 31.2

 

CERTIFICATION

PURSUANT TO RULE 13a-14 AND 15d-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

I, Sten L. Gustafson certify that:

 

1.I have reviewed this Annual Report on Form 10-Q for the quarter ended September 30, 2023 of Pyrophyte Acquisition Corp.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

Date: November 20, 2023 By: /s/ Sten L. Gustafson
    Sten L. Gustafson
    Chief Financial Officer and Director
(Principal Financial and Accounting Officer)

 

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. 1350

(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

 

In connection with the Quarterly Report of Pyrophyte Acquisition Corp. (the “Company”) on Form 10-Q for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bernard J. Duroc-Danner, Chief Executive Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 20, 2023 By: /s/ Bernard J. Duroc-Danner
    Bernard J. Duroc-Danner
    Chief Executive Officer and Director
(Principal Executive Officer)

 

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. 1350

(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

 

In connection with the Quarterly Report of Pyrophyte Acquisition Corp.. (the “Company”) on Form 10-Q for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sten L. Gustafson, Chief Financial Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 20, 2023 By: /s/ Sten L. Gustafson
    Sten L. Gustafson
    Chief Financial Officer and Director
(Principal Financial and Accounting Officer)

 

 

v3.23.3
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2023
Nov. 20, 2023
Document Information Line Items    
Entity Registrant Name PYROPHYTE ACQUISITION CORP.  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   14,005,087
Amendment Flag false  
Entity Central Index Key 0001848756  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Sep. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Shell Company true  
Entity Ex Transition Period false  
Document Quarterly Report true  
Document Transition Report false  
Entity Incorporation, State or Country Code E9  
Entity File Number 001-40957  
Entity Tax Identification Number 00-0000000  
Entity Address, Address Line One 3262 Westheimer Road  
Entity Address, Address Line Two Suite 706  
Entity Address, City or Town Houston  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 77098  
City Area Code +1 (345)  
Local Phone Number 769-4900  
Entity Interactive Data Current Yes  
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant    
Document Information Line Items    
Trading Symbol PHYT.U  
Title of 12(b) Security Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant  
Security Exchange Name NYSE  
Class A Ordinary Shares, par value $0.0001 per share    
Document Information Line Items    
Trading Symbol PHYT  
Title of 12(b) Security Class A Ordinary Shares, par value $0.0001 per share  
Security Exchange Name NYSE  
Redeemable Warrants, each exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share    
Document Information Line Items    
Trading Symbol PHYT WS  
Title of 12(b) Security Redeemable Warrants, each exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share  
Security Exchange Name NYSE  
v3.23.3
Condensed Balance Sheets - USD ($)
Sep. 30, 2023
Dec. 31, 2022
ASSETS    
Cash $ 1,933 $ 13,372
Prepaid expenses 56,180 298,422
Extension contribution due from Sponsor 480,000
Total current assets 538,113 361,294
Investments and cash held in Trust Account 97,110,088 209,651,193
Total Assets 97,648,201 210,012,487
LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT    
Accounts payable 63,842
Promissory note – extension loan 480,000
Promissory note – working capital loan 177,055
Accrued expenses 525,209 222,020
Total current liabilities 1,261,106 222,020
Deferred underwriting fees payable 8,443,750 8,443,750
Derivative warrant liabilities 1,314,218 1,516,406
Deferred legal fees 2,034,799 1,322,174
Total Liabilities 13,033,873 11,504,350
Commitments and Contingencies (Note 5)
Class A ordinary shares subject to possible redemption, $0.0001 par value; 8,973,837 and 20,125,000 shares at $10.86 and 10.41 per share at September 30, 2023 and December 31, 2022, respectively 97,490,079 209,551,185
Shareholders’ Deficit    
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding
Additional paid-in capital
Accumulated deficit (12,896,254) (11,043,551)
Total shareholders’ deficit (12,895,751) (11,043,048)
Total Liabilities, Ordinary Shares Subject to Possible Redemption, and Shareholders’ Deficit 97,648,201 210,012,487
Class A Ordinary Shares    
Shareholders’ Deficit    
Ordinary Shares, Value 503
Class B Ordinary Shares    
Shareholders’ Deficit    
Ordinary Shares, Value 503
Related Party    
ASSETS    
Due from related party 49,500
LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT    
Due to related party $ 15,000
v3.23.3
Condensed Balance Sheets (Parentheticals) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Ordinary shares subject to possible redemption, per share (in Dollars per share) $ 10.56  
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Class A Ordinary Shares Subject to Possible Redemption    
Ordinary shares subject to possible redemption, par value (in Dollars per share) $ 0.0001 $ 0.0001
Ordinary shares subject to possible redemption, shares authorized 8,973,837 20,125,000
Ordinary shares subject to possible redemption, per share (in Dollars per share) $ 10.86 $ 10.41
Class A Ordinary Shares    
Ordinary shares, par value (in Dollars per share) $ 0.0001 $ 0.0001
Ordinary shares, shares authorized 200,000,000 200,000,000
Ordinary shares, shares issued 5,031,250 0
Ordinary shares, shares outstanding 5,031,250 0
Class B Ordinary Shares    
Ordinary shares, par value (in Dollars per share) $ 0.0001 $ 0.0001
Ordinary shares, shares authorized 20,000,000 20,000,000
Ordinary shares, shares issued 0 5,031,250
Ordinary shares, shares outstanding 0 5,031,250
v3.23.3
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
General and administrative expenses $ 547,392 $ 254,584 $ 1,574,892 $ 2,034,395
Loss from operations (547,392) (254,584) (1,574,892) (2,034,395)
Change in fair value of derivative warrant liabilities 683,395 2,830,625 202,188 8,271,893
Gain on investments held in Trust Account 1,226,102 1,023,730 4,723,284 1,391,133
Other income 66 83
Net income $ 1,362,105 $ 3,599,837 $ 3,350,580 $ 7,628,714
Class A Ordinary Shares Subject to Possible Redemption        
Weighted average shares outstanding of ordinary shares, Basic (in Shares) 8,973,837 20,125,000 13,589,520 20,125,000
Basic and diluted net income per share (in Dollars per share) $ 0.1 $ 0.14 $ 0.18 $ 0.3
Non-Redeemable Ordinary Shares        
Weighted average shares outstanding of ordinary shares, Basic (in Shares) 5,031,250 5,031,250 5,031,250 5,031,250
Basic and diluted net income per share (in Dollars per share) $ 0.1 $ 0.14 $ 0.18 $ 0.3
v3.23.3
Condensed Statements of Operations (Unaudited) (Parentheticals) - $ / shares
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Class A Ordinary Shares Subject to Possible Redemption        
Weighted average shares outstanding of ordinary shares, Diluted 8,973,837 20,125,000 13,589,520 20,125,000
Diluted net income per share $ 0.10 $ 0.14 $ 0.18 $ 0.30
Non-Redeemable Ordinary Shares        
Weighted average shares outstanding of ordinary shares, Diluted 5,031,250 5,031,250 5,031,250 5,031,250
Diluted net income per share $ 0.10 $ 0.14 $ 0.18 $ 0.30
v3.23.3
Condensed Statements of Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit (Unaudited) - USD ($)
Class A
Ordinary Shares Subject to Possible Redemption
Class A
Ordinary Shares
Class B
Ordinary Shares
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2021 $ 206,281,250 $ 503 $ (18,416,733) $ (18,416,230)
Balance (in Shares) at Dec. 31, 2021 20,125,000 5,031,250      
Net income 1,119,132 1,119,132
Balance at Mar. 31, 2022 $ 206,281,250 $ 503 (17,297,601) (17,297,098)
Balance (in Shares) at Mar. 31, 2022 20,125,000 5,031,250      
Balance at Dec. 31, 2021 $ 206,281,250 $ 503 (18,416,733) (18,416,230)
Balance (in Shares) at Dec. 31, 2021 20,125,000 5,031,250      
Extension contribution due from Sponsor          
Net income           7,628,714
Balance at Sep. 30, 2022 $ 207,590,429 $ 503 (12,097,198) (12,096,695)
Balance (in Shares) at Sep. 30, 2022 20,125,000 5,031,250      
Balance at Mar. 31, 2022 $ 206,281,250 $ 503 (17,297,601) (17,297,098)
Balance (in Shares) at Mar. 31, 2022 20,125,000 5,031,250      
Remeasurement of Class A ordinary shares to redemption value $ 285,449 (285,449) (285,449)
Net income 2,909,745 2,909,745
Balance at Jun. 30, 2022 $ 206,566,699 $ 503 (14,673,305) (14,672,802)
Balance (in Shares) at Jun. 30, 2022 20,125,000 5,031,250      
Remeasurement of Class A ordinary shares to redemption value $ 1,023,730   (1,023,730) (1,023,730)
Net income 3,599,837 3,599,837
Balance at Sep. 30, 2022 $ 207,590,429 $ 503 (12,097,198) (12,096,695)
Balance (in Shares) at Sep. 30, 2022 20,125,000 5,031,250      
Balance at Dec. 31, 2022 $ 209,551,185 $ 503 (11,043,551) (11,043,048)
Balance (in Shares) at Dec. 31, 2022 20,125,000 5,031,250      
Remeasurement of Class A ordinary shares to redemption value $ 2,347,624 (2,347,624) (2,347,624)
Net income 1,005,015 1,005,015
Balance at Mar. 31, 2023 $ 211,898,809 $ 503 (12,386,160) (12,385,657)
Balance (in Shares) at Mar. 31, 2023 20,125,000   5,031,250      
Balance at Dec. 31, 2022 $ 209,551,185 $ 503 (11,043,551) (11,043,048)
Balance (in Shares) at Dec. 31, 2022 20,125,000 5,031,250      
Balance at Jun. 30, 2023 $ 95,783,977 $ 503 (12,712,257) (12,711,754)
Balance (in Shares) at Jun. 30, 2023 8,973,837 5,031,250      
Balance at Dec. 31, 2022 $ 209,551,185 $ 503 (11,043,551) (11,043,048)
Balance (in Shares) at Dec. 31, 2022 20,125,000 5,031,250      
Redemption of Class A ordinary shares           $ (117,744,389)
Redemption of Class A ordinary shares (in Shares)           (11,151,163)
Extension contribution due from Sponsor           $ 480,000
Net income           3,350,580
Balance at Sep. 30, 2023 $ 97,490,079 $ 503 (12,896,254) (12,895,751)
Balance (in Shares) at Sep. 30, 2023 8,973,837 5,031,250      
Balance at Mar. 31, 2023 $ 211,898,809 $ 503 (12,386,160) (12,385,657)
Balance (in Shares) at Mar. 31, 2023 20,125,000   5,031,250      
Redemption of Class A ordinary shares $ (117,744,389)
Redemption of Class A ordinary shares (in Shares) (11,151,163)          
Conversion of Class B ordinary shares to Class A ordinary shares $ 503 $ (503)